

## Curriculum Vitae

### **Bankole Akindeinde Johnson**

DSc, MD, MBChB, MPhil, FRCPsych, DFAPA, Dip-ABAM, Dip-ABDA, FACFEI

Professor of Biomedical Sciences, Larkin University Miami, Florida

Founder & CEO, Casa Privée USA

Founder & Chief Medical Officer, Adial Pharmaceuticals Inc

Email: [Kolej@me.com](mailto:Kolej@me.com)

Founder and Chief Executive Officer

Casa Privée ([www.casaprivee.com](http://www.casaprivee.com)), Miami, Florida

Foreign languages: French and Spanish



**Date:** October 2024

## Table of Contents

- Education
- Postgraduate Training
  - Certifications
  - Medical Licensures
  - Employment History
- Academic Appointments and Other Employment*
  - Honors and Awards
  - Clinical Activities
- Institutional Service: Overview, Inpatient, Outpatient
  - National and Local Services
- Positions Held in Professional Organizations, Editorial Boards and Positions, Service on National Grant Review Panels, Study Sections, and Committees*
  - Consultantships
- Regular Continuing Education Lectures Presented
  - Local Community Activities
  - Management Courses Taken
  - Teaching Service
- Classroom/Laboratory, Clinical, Instructional Development*
- PhD Dissertations Directed, Membership on Supervising Committees, Students and Postdoctoral Fellows Supervised, and Faculty Membership
  - Media and Community Presentations
    - Grant Support
  - Patents, Inventions, and Copyrights
  - Publications
- Peer-reviewed Journal Articles, Books, Book Chapters, Theses, Published Abstracts, Book Reviews, Letters to the Editor, Other Professional Communications, Monographs*
  - Major Invited Speeches/Lectures
- Presentations at National and International Conferences

## **Education**

<i>Year(s)</i>	<i>Degree</i>	<i>Major</i>	<i>Institution/Location</i>
1970-1975	Diploma	General	King's College, Lagos, Nigeria
1975-1977	Diploma	General	Davies' College, Sussex, England
1977	Diploma	French Studies	Institute Catholique de Paris, Paris, France
1977-1982	<i>Medicinae Baccalaureum et Chirurgiae Baccalaureum</i>	M.D. equivalent	University of Glasgow, Scotland
1983	Full registration, UK		University of Glasgow, Scotland
1989	M.R.C.Psych. (UK Board Certification in Psychiatry)	UK Board Certification in Psychiatry	Royal College of Psychiatrists
1991	Master of Philosophy thesis in research methodology and classification	Master of Science (equivalent) in Neuro-psychiatry	University of London
1993	(T) Psych	European-Wide Board Certification in Psychiatry	Royal College of Psychiatrists/General Medical Council, UK
1993	Doctoral thesis in Neuropsychopharmacology; <i>Medicinae Doctorem</i> and fellowship program	Ph.D. (equivalent) in Biomedical Sciences	Conducted at Oxford University/Degree from University of Glasgow
1999	Diploma	Diplomate of the American Board of Forensic Medicine (Identification Number 18496)	The American College of Forensic Examiners Institute
2002, 2013	U.S. Board Certification	Psychiatry	American Board of Psychiatry and Neurology, Inc.
2004	Doctor of Science (D.Sc.) – the highest doctoral degree awarded in the UK for contributions to science	Medicine	University of Glasgow, Scotland

## **Postgraduate Training**

<i>Years</i>	<i>Degree</i>	<i>Institution/Location</i>
1983-1984	Postgraduate in critical care & anaesthesiology	Scotland & University of Glasgow
1984-1985	Senior house officer, psychiatry	Scotland & University of Glasgow

1985-1986  
1986-1988

East London psychiatry training scheme  
Maudsley psychiatry training scheme  
(Contact: Sir Professor Simon Wessely,  
[simon.wessely@kcl.ac.uk](mailto:simon.wessely@kcl.ac.uk))

University of London, London

## **Certifications**

<i>Year</i>	<i>Board</i>
1989	Royal College of Psychiatrists (UK)
2010-present	American Board of Addiction Medicine
2012	United States Department of Justice, Drug Enforcement Administration, Controlled Substance Registration
2012	Specialist accreditation in Europe (General Medical Council – UK)
2013	Texas Department of Public Safety, Texas Controlled Substances Registration
2013-present	American Board of Psychiatry and Neurology, Inc. (General Psychiatry)
2015-present	Lifetime Member, American Board of Disability Analysts
2017- present	American Board of Preventative Medicine in Addiction

## **E.C.F.M.G.**

May 8, 1996 - #0-528-549-9

## **Medical Licensures**

Maryland, active  
Texas, active  
Virginia, active  
Florida, active  
Maine, inactive

## **Employment History**

### **Academic Appointments**

<i>Years</i>	<i>Position</i>	<i>Institution/Location</i>
1988-1991	Honorary Senior Registrar (Instructor equivalent in General/Forensic Psychiatry)	Institute of Psychiatry/University of London
1991-1993	Wellcome Research Fellow & Honorary Senior Registrar (Assistant Professor equivalent in Addiction Psychiatry) (Contact: Prof. Phil Cowen, <a href="mailto:phil.cowen@psych.ox.ac.uk">phil.cowen@psych.ox.ac.uk</a> )	Oxford University
1993-1997	Assistant Professor & Teaching Fellow of Psychiatry and Behavioral Sciences	University of Texas – Houston Health Science Center
1997-1998	Associate Professor of Psychiatry and Behavioral Sciences	University of Texas – Houston Health Science Center
1998-2000	Professor of Psychiatry and Professor of Pharmacology; Deputy Chairman for Research; Chief, Division of Alcohol and Drug Addiction	The University of Texas Health Science Center at San Antonio
2000-2004	Wurzbach Distinguished Professor of Psychiatry and Professor of Pharmacology (Tenured); Deputy Chairman for Research; Chief, Division of Alcohol and Drug Addiction	The University of Texas Health Science Center at San Antonio
2004-2013	Alumni Professor of Psychiatry and Neurobehavioral Sciences and Professor of	University of Virginia

2006-2013	Neuroscience; Chairman, Department of Psychiatry and Neurobehavioral Sciences Professor of Medicine	University of Virginia
2013-2014	Professor of Psychiatry, Professor of Anatomy and Neurobiology, Professor of Pharmacology and Chairman of the Department of Psychiatry	University of Maryland School of Medicine
2014 March - March 2019	The Dr. Irving J. Taylor Professor and Chair in the Department of Psychiatry, Professor of Anatomy & Neurobiology, Professor of Pharmacology, Professor of Neurology Director, Brain Science Research Consortium Unit	University of Maryland School of Medicine
Feb – Dec 2019	Professor of Anatomy & Neurobiology, Pharmacology, Neurology, Medicine, and Psychiatry, & Director of the Brain Consortium Research Unit	
Jan 2020-	Founder, Executive Chairman, and CEO, Privée Clinics, Miami, Florida Founder, Chief Medical Officer (previously Chairman), Adial Pharmaceuticals Inc.	

### **Other Employment**

1982-1983	House Physician	Stonehouse Hospital, Scotland
1983	House Surgeon	Western Infirmary, Scotland
1983-1984	Senior House Physician, Anesthesiology & Critical Care	Monklands Teaching Hospital, Scotland

### **Professional Society**

#### **Memberships**

1986-present	Member, British Association of Psychopharmacologists
1989-present	Member, British Neuropsychiatry Association
1989-2005, 2010-present	Fellow, Royal Society of Medicine
1994-present	Active Member, New York Academy of Sciences
1995-present	Member, American Society of Clinical Psychopharmacology
1995-present	Member, Research Society on Alcoholism
1995-present	Member, Society for Neuroscience
1997-present	Member, The College on Problems of Drug Dependence
1997-present	Fellow, Collegium Internationale Neuro-psychopharmacologicum
1999-present	Member, American College of Neuropsychopharmacology
1999-present	Diplomate Member, The American College of Forensic Examiners Institute
2000-2006	Member, Texas Society of Psychiatric Physicians
2000-present	Member, American Psychiatric Association
2001-present	Member, Society of Biological Psychiatry
2002-present	Member, The Science Advisory Board
2003-present	Member, International Society for Biomedical Research on Alcoholism
2007-present	Member, Old Dominion Medical Society
2007-present	Member, National Academy of Neuropsychology
2008-present	Distinguished Fellow, American Psychiatric Association
2010-present	2013-present

Member, Association for Psychologica	I Science Fellow, American College of Neuropsychopharmacology Fellow, American College of Forensic Examiners Institute
2014-present	Member, Association for Academic Minority Physicians
2018-present	Member, Council on Research, American Psychiatric Association
2024	Diplomate, Board of the American Academy of Stem Cell Physicians

### **Honors and Awards**

1974	Prizes in French and English Literature
1975	Prizes for Biology and Chemistry
1978	Distinction in Biology, University of Glasgow
1981	Distinction for series of Psychiatric Case Studies of Schizophrenic Families, University of Glasgow
1980-1982	National Scholarship
1991-1993	Wellcome Research Scientist Development Award, United Kingdom
1991-present	Best Doctors in the United Kingdom
1998	Finalist, at the XXIst Collegium Internationale Neuro-psychopharmacologicum Congress Young Psychopharmacologist Award
1998-2002	NIAAA Clinical and Treatment Research Study Section (AA-3) Member
1999	U.S. Govt./NIAAA representative to establish bi-national collaborative research links with South Africa
2001	Dan Anderson Research Award, Hazelden Foundation
2002	Chairman, NIAAA Alcohol Research Center Applications (ZAA1 BB, 73)
2002	Senior Scholar of Distinction, National Medical Association
2003- present	Examiner for American Board of Psychiatry and Neurology
2003	Inductee, Texas Hall of Fame for Science, Mathematics and Technology
2003	Inductee, Faces of the Medical Community
2003	Adolf Meyer Research Award, Third Annual Bexar County Family Support Conference
2004-2007	Appointed to the National Advisory Council for NIH/NIDA
2004-2007	Member, Medications Development Subcommittee of NIDA's Advisory Council on Drug Abuse
2004-present	Member, Extramural Advisory Board for NIH/NIAAA
2005-2009	Member, Medications Development Scientific Advisory Board for NIH/NIDA
2006	American Psychiatric Association, Distinguished Psychiatrist Lecturer Award (for outstanding achievement in the field of psychiatry as an educator, researcher, and clinician)
2006-present	NIH Roadmap Consultant
2007-present	Fellow, Royal College of Psychiatrists (FRCPsych.)
2007, 2009-2010	Listed in Best Doctors in America® (Best Doctors, Inc.)
2008-present	Distinguished Fellow, American Psychiatric Association
2009	American Psychiatric Association, Solomon Carter Fuller Award (honoring an individual who has pioneered in an area that has benefited significantly the quality of life for Black people)
2010-present	Fellow, American College of Neuropsychopharmacology
2013	Jack Mendelson Award, NIAAA

2017 Governor's citation, Maryland Heroin and Opioid Emergency Task Force  
2018 Dean Reece Cup Award, best performing department in the UMSOM  
2019 R. Brinkley Smithers Distinguished Scientist Award, American Society for  
Addiction Medicine, for advancing the scientific understanding of addiction



## **Clinical Activities**

### **Brief Overview of Clinical Research**

My research focus is in the neuropsychopharmacology of addiction. My work integrates the neuroscience and behavioral aspects of addiction medicine and seeks to develop an understanding of the basic underpinnings of drug-seeking behavior and to devise effective medication treatments. My projects involve the areas of clinical trials, human laboratory studies, neuroimaging studies, and molecular genetics.

### **Inpatient**

1993-1998: University of Texas – Houston Health Science Center

I was involved in the supervision of volunteer subjects participating in designated protocols admitted to the NIH-sponsored University Clinical Research Center.

1998-2004: The University of Texas Health Science Center at San Antonio

I continued my inpatient work at the University Clinical Psychopharmacology Laboratory in the conduct of the NIAAA-sponsored Project COMBINE Pilot 1 study.

### **Outpatient**

1993-1998: University of Texas – Houston Health Science Center

I was responsible for the treatment and welfare of all outpatients and human laboratory subjects attending the Clinical Laboratory and Experimental Alcohol Research Center, primarily consisting of those with substance dependence and related mental health problems.

1998-2004: The University of Texas Health Science Center at San Antonio

I continued providing supervision of outpatient services at the Treatment Research Center. Patient load consisted of over 300 substance-dependent individuals per annum.

2005-2013: University of Virginia Center for Addiction Research and Education

This new outpatient facility has provided NIH-funded clinical research to the community of Charlottesville, Virginia. The primary focus has been to identify pharmacological treatments for alcohol cocaine, methamphetamine, and nicotine dependence, as well as to promote education in the addiction sciences. An important aspect of this clinical facility is technology transfer, thereby serving to bridge the gap between research and community treatment.

2014- Dec 2019: Clinical Neurobehavioral Center (CNC)

I am the Director of this state-of-the-art inpatient facility, which was established to research and treat a spectrum of addiction and impulse control disorders. The Clinical Neurobehavioral Center (CNC) is currently conducting research on patients with alcohol use disorders in relation to genetic markers and pharmacological treatments. In addition to these subsets of clinical trials, the Center also serves as the primary point for VIP patients, who are seeking medication-based treatments for addiction disorders that primarily include alcohol use disorders.

The facility also houses the award-winning Maryland Center of Excellence on Problem Gambling, which is a collective resource that maintains a problem gambling counselor referral list and network of problem gambling treatment providers. The Maryland Center of Excellence on Problem Gambling also trains counselors, educators, prevention specialists, and other health care and social service providers. Additionally, the center has developed and coordinates prevention and outreach community programs.

## **Administrative Service**

## **Institutional Service**

1998-2004 **Deputy Chairman for Research, Department of Psychiatry, The University of Texas Health Science Center at San Antonio**

I worked with other division chiefs within the Department to promote research. This included coordinating the development of the research infrastructure, identifying funding opportunities, developing a research curriculum for faculty development, and organizing research-based educational programs within the Department.

1998-2004 **Chief, Division of Alcohol and Drug Addiction in the Department of Psychiatry, The University of Texas Health Science Center at San Antonio**

I built a strong research and administrative core for this Division and was responsible for the clinical supervision of all physicians, nurses, psychologists, social workers, and other health care workers affiliated with the Division.

2004-2013 **Chairman, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia**

I was responsible for managing and fostering growth within a department of 50 faculty and 75 affiliated faculty, as well as recruiting faculty who would enhance the Department's dedication to high-quality teaching. The Department's name was changed to the Department of Psychiatry and Neurobehavioral Sciences, which highlighted the new focus on a balance among clinical work, teaching, and research. In addition, a culture of individual responsibility and support for entrepreneurial enterprise was nurtured. The results were that later, the Department: had a faculty that was split almost evenly between researchers and clinicians; produced dramatically more publications and presentations every year; dramatically increased its funding from R01 National Institutes of Health grants, and reversed its poor financial performance to produce consistent surpluses and build a healthy capital reserve account.

2013-present **The Dr. Irving J. Taylor Professor and Chair, Department of Psychiatry, University of Maryland School of Medicine**

As the appointed Dr. Irving J. Taylor Professor and Chair, I am responsible for overseeing one of the largest Departments within the School of Medicine, with 117 part- and full-time faculty on hire.

My clinical expertise is in the fields of addiction; and my research incorporates neuroimaging evaluations into drug interaction studies to identify the site-specific effects of abused drugs, allowing me to evaluate the effectiveness of potential medications for the treatment of addictions. My strong clinical and research background has subsequently enabled me to encourage the cross-collaborative nature of transdisciplinary science, spanning the breadth of the Department -- and School of Medicine -- through the newly formed Research Steering Committee and Brain Science Research Consortium Unit (BSRCU). Additionally, the Clinical Neurobehavioral Center (CNC), which was built and established under my direction, serves as a vital point of collaboration among impulse control scientists and also as a facility to help those with disorders, ranging from alcohol use to problem gambling, and more.

Finally, I am in the process of directing the establishment of a pioneering Office of Special Projects, as well as developing urban conflict outreach initiatives, to build organic community relationships and to facilitate impactful community interventions.

**Institutional Service**

1993-1998	Research Planning Committee (University of Texas – Houston Health Science Center, Dept. of Psychiatry)	Member
1993-1995	Continuous Quality Improvement (CQI) committee (University of Texas –Houston Health Science Center, Dept. of Psychiatry)	Member
1994-1998	Pharmacy and therapeutics committee (University of Texas – Houston Health Science Center, Dept. of Psychiatry)	Chairman
1994-1996	Residency Training Committee (University of Texas – Houston Health Science Center, Dept. of Psychiatry)	Member
1994-1996	Didactic curriculum committee for the residency program (University of Texas – Houston Health Science Center, Dept. of Psychiatry)	Chairman
1996-1998	University of Texas – Houston Health Science Center Local Area Networks & Information Technology Manager. This committee devises policy for the implementation and supervision of all computer-based technologies on-campus	Member
1999-2004	Web-Site Committee	Member and Senior Consultant
1999-2004	Research Program Oversight Group	Chairman
1999-2004	Center for Addictions, Mental Illness and Psychoactive Drugs (CAMP) Research Consortium	Director
1999-2004	Maas/Maddux Intramural Research Fellowship Review Committee	Member
1999-2004	Friends of Psychiatry Intramural Research Fellowship Review Committee	Member
1999-2004	The University of Texas Health Science Center at San Antonio Space Committee	Member
	Patient Care Space Subcommittee	Chairman
	Research Space Subcommittee	Member
1999-2001	The University of Texas Health Science Center at San Antonio Search Committee for Director of the Institute for Drug Development of the Cancer Therapy and Research Center (IDD)	Member
1999-2004	Presidential Distinguished Scholars Award Committee	Member
1999-2004	South Texas Health Research Center Review Committee	Reviewer
1999-2004	Virtual Campus Think Tank Group. This group participated in the conceptualization and development of a virtual campus for research collaboration made possible by a \$5 million grant.	Member
1999-2001	Review committee for the Competitive Research Enhancement Fund. This grant program funded research programs for new University of Texas Health Science Center faculty.	Member

1999-2004	The University of Texas Health Science Center at San Antonio Search Committee for Dean of the Graduate School of Biomedical Sciences	Member
2000	The University of Texas Health Science Center at San Antonio Search Committee for Associate Dean for Research	Member
2000-2004	The University of Texas Health Science Center at San Antonio/University of Texas at San Antonio Collaborative Educational and Research Activities Committee – Neurosciences Working Group	Member
2001-2004	The University of Texas Health Science Center at San Antonio Institutional Strategic Planning Committee	Member
2001-2004	The University of Texas Health Science Center at San Antonio Faculty Promotions, Tenure, and Appointments Committee	Member
2005-2013	University of Virginia – Dean’s Department of Internal Medicine Chair Search Committee	Member
2005-2013	University of Virginia – Neuroscience Institute Development Committee	Member
2005-2013	University of Virginia School of Medicine – Indigent Care and Uninsured Patients Task Force	Chairman
2005-2013	University of Virginia – Review Committee for the Reappointment of the Chairman, Department of Neurosurgery	Chairman
2007-2013	University of Virginia Medical Reserve Corps (Disaster Response)	Captain

**National and Local Service**

**Positions Held in Professional Organizations**

1986	Junior doctors’ representative, Chief Resident & Mess President
1987	Students’ representative, University of Glasgow
1986-1987	British Medical Association place of work representative for doctors in training
1999	Research Society on Alcoholism Program Committee for the Annual Scientific Meeting to be held in 2000
2000-2003	College on Problems of Drug Dependence – Media Relations Committee
2005-2009	World Federation of Societies of Biological Psychiatry – Task Force on Addiction Disorders
2006-2009	American Psychiatric Association – Council on Addiction Psychiatry
2009-2010	American Psychiatric Association – Council on Adult Psychiatry
2009-present	American College of Neuropsychopharmacology – Alcohol Clinical Trials Initiative (ACTIVE) Workgroup
2011-2013	American College of Neuropsychopharmacology – Education & Training Committee
2013	American College of Neuropsychopharmacology – Minority Task Force
2015	Governor’s Heroin and Opioid Emergency Task Force, resulting in the publication of the Interim and Final Reports

### **Editorial Boards and Other Editorial Positions**

1993-present	Reviewer for peer-reviewed national and international scientific journals including: <i>Addiction</i> ; <i>Addiction Biology</i> ; <i>Addictive Behaviors</i> ; <i>Alcohol</i> ; <i>Alcohol and Alcoholism</i> ; <i>Alcoholism: Clinical and Experimental Research</i> ; <i>American Family Physician</i> ; <i>The American Journal of Managed Care</i> ; <i>The American Journal of Psychiatry</i> ; <i>The American Journal on Addictions</i> ; <i>Archives of General Psychiatry</i> (now <i>JAMA Psychiatry</i> ); <i>Archives of Internal Medicine</i> (now <i>JAMA Internal Medicine</i> ); <i>BMJ Point of Care</i> (monograph); <i>Biological Psychiatry</i> ; <i>Bipolar Disorders</i> ; <i>CNS &amp; Neurological Disorders – Drug Targets</i> ; <i>CNS Drugs</i> ; <i>Critical Care Medicine</i> ; <i>Current Drug Abuse Reviews</i> ; <i>Drug and Alcohol Dependence</i> ; <i>European Psychiatry</i> ; <i>Expert Opinion on Pharmacotherapy</i> ; <i>Human Brain Mapping</i> ; <i>Human Psychopharmacology: Clinical and Experimental</i> ; <i>The International Journal of Neuropsychopharmacology</i> ; <i>JAMA: The Journal of the American Medical Association</i> ; <i>The Lancet</i> ; <i>Nature Medicine</i> ; <i>Nature Reviews Neuroscience</i> ; <i>Neuropsychopharmacology</i> ; <i>New England Journal of Medicine</i> ; <i>Nordic Journal of Psychiatry</i> ; <i>Peptides</i> ; <i>Pharmacopsychiatry</i> ; <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> ; <i>Psychological Medicine</i> ; <i>Psychology of Addictive Behaviors</i> ; <i>Psychopharmacology</i> , and <i>Revista Brasileira de Psiquiatria</i>
1996-1997	Editorial Board of <i>Internet Medicine</i>
1997-2009	Editorial Board of <i>The International Journal of Neuropsychopharmacology</i>
1999-2006	Editorial Advisory Board of <i>Alcohol Research &amp; Health</i>
1999-present	Editorial Advisory Board of <i>Medscape Mental Health</i>
2004-present	Editorial Board of <i>Current Psychiatry Reviews</i>
2005-present	Editorial Board of <i>Addictive Disorders &amp; Their Treatment</i>
2006-present	Managing Editorial Board of <i>Frontiers in Bioscience</i>
2008-present	Executive Guest Editor on Editorial Board of <i>Current Pharmaceutical Design</i>
2008-present	Editorial Board of <i>American Journal of Translational Research</i>
2009-2016	Associate Editor of the Editorial Board of <i>The American Journal of Psychiatry</i>
2010-2011	Field Editor-in-Chief of <i>Frontiers in Psychiatry</i>
2011-present	Board of Field Editors of <i>Alcoholism: Clinical and Experimental Research</i>
2011-present	Editorial Board of <i>World Journal of Methodology</i>
2012-2017	Editorial Board of <i>Journal of Studies on Alcohol and Drugs</i>
2012-present	Editorial Board of <i>The American Journal of Drug and Alcohol Abuse</i>

### **Service on National Grant Review Panels, Study Sections, and Committees**

1993-1997	National Institutes of Health Special Review Committee
1996-present	Scientific Merit reviewer for grants from the Department of Veterans Affairs
1997-present	National Steering Committee for Combining Medications and Behavioral Interventions (COMBINE) in the treatment of Alcoholism Project (NIAAA-sponsored multi-site study)
1997-2002	Psychopharmacology Intervention subcommittee for Combining Medications and Behavioral Interventions (COMBINE) in the treatment of Alcoholism Project (NIAAA-sponsored multi-site study)
1997-present	Publications subcommittee for Combining Medications and Behavioral Interventions (COMBINE) in the treatment of Alcoholism Project (NIAAA-sponsored multi-site study)

1998-2002 NIAAA Clinical and Treatment Research Review Committee – IRB Study Section (AA3)

1998 NIAAA Special Emphasis Study Section on alcohol and HIV-related disorders

1998 NIAAA Special Emphasis Study Section on alcoholism and adolescents

1998 NIAAA/FDA Workshop on developing medications for the treatment of alcoholism

1998 NIDA/VA Medications Development Workshop on the use of a buprenorphine/naloxone combination for the treatment of opiate dependence

1998 NIAAA-sponsored Workshop on Preclinical Medications Development

1999 Member of the Search committee for the Head of the Clinical Laboratories at NIAAA

1999-2001 NIAAA SBIR/STTR Special Emphasis IRG study section – Phase II Proposal Review

1999 NIAAA representative for collaborative research with the University of the Orange Free State, South Africa

1999 External advisor, promotions and tenure committee for the rank of professor - University of the Texas – Dallas

1999 NIAAA ICTAB-9 Scholarship Committee

1999 NIH ad hoc Reviewer for the Brain Disorders and Clinical Neuroscience Committee (NIH/BDCN-6)

1999 University of Texas – Dallas Faculty Promotion Review Committee

1999 NIAAA Special Review Group for developing medications for the treatment of alcoholism

1999 NIDA Special Emphasis Panel (SEP) Review Group cooperative agreement applications in response to NIDA RFA “Strategic Program for Innovative Research on Cocaine (and other psychomotor Stimulants) Addiction Pharmacotherapy” (SPIRCAP ZDA1 KXA-N(18))

1999-2001 NIAAA Researcher in Residence Program – Research Collaborator

2000-present CBS HealthWatch Physicians Network, Member

November 2000 NIAAA Special Emphasis Panel IRG 2001/01 Council ZAA1 BB01 1

February 2001 NIAAA B-START Special Review Panel

July 2001 Acting Chair, NIDA Special Emphasis IRG Review Panel

July 2001 Texas Commission on Alcohol and Drug Abuse Drug Demand Reduction Advisory Committee; Texas State Legislature, Austin

2001-present Waggoner Center for Alcohol and Addiction Research, University of Texas at Austin – Scientific Review Committee

2002 Chairman, NIAAA Alcohol Research Center Applications (ZAA1 BB, 73)

2002 NIH Loan repayment program IRG, April 29, 2002

2002 NIAAA (Division of Clinical and Prevention Research) Workshop on Self-Report and Biochemical Measures of Alcohol Consumption

2005-present Reviewer, U.S. Department of Veterans Affairs Cooperative Studies Program

2006-present Member, Advanced Studies in Medicine’s Therapeutic Area Advisory Board

2012-present Chairman, SAMHSA and NIAAA Consensus Panel on New Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities (resulted in the publication of “Medication for the Treatment of Alcohol Use Disorder: A Brief Guide,” found here: <http://store.samhsa.gov/shin/content/SMA15-4907/SMA15-4907.pdf>)

2015 Member, NIH Pioneer Review Award Committee  
 2015 Workgroup Co-Chair, Maryland Heroin and Opioid Task Force  
 2016 Member, Blueprint Neurotherapeutics Network (BPN) Review Panel  
 2017 NIAAA Board of Scientific Counselor's Meeting, Review of Section of Clinical Psychoneuroendocrinology of Neuropsychopharmacology (CPN), October 2-3, 2017

**Consultantships**

1997-2000 Consultant/collaborative relationship with DesArc (Chicago) to develop co-registration and brain mapping software for SPECT imaging  
 1998-2013 Consultant for biotechnology companies in the field of addiction neuroscience (e.g., Scheer and Company, Connecticut)  
 1999-2013 Consultant for Investigational Drugs Weekly Highlights  
 1999-2013 Consultant and Scientific Advisory Board to the Medical University of South Carolina on NIAAA application for RFP AA-99-005 Alcohol Research Center Grants  
 2000-2005 Consultant for Alkermes, Inc. to develop research protocols for the treatment of alcoholism  
 2003-2008 Consultant for Johnson & Johnson (Ortho-McNeil Pharmaceutical, Inc. / Ortho-McNeil Janssen Scientific Affairs, LLC) to develop strategies for pharmacological treatment of alcohol dependence  
 2005 Consultant for GlaxoSmithKline  
 2006 Consultant for Sanofi-Aventis  
 2006-2009 Consultant for TransOral Pharmaceuticals, Inc. / Transcept Pharmaceuticals, Inc.  
 2007-2010 Consultant for Organon  
 2008-present Founder and Chairman for ADial Pharmaceuticals, Inc., a NASDAQ company  
 2009-2010 Consultant for Eli Lilly and Company  
 2009-present Founder & CEO, Psychological Education Publishing Company (PEPCo), LLC

**Regular Continuing Education Lectures Presented**

1996-2001 Quarterly presentations for the Compass Medical Education Network (part of the Rush/Presbyterian Medical Education System) to prepare physicians and students for the USMLE.  
 Approx. 140 Category A CMEs/annum

**Local Community Activities**

1993-2013 Local church community outreach worker  
 1996-2013 Substance abuse and HIV counseling presentations at health fairs  
 1999-2004 San Antonio Fighting Back Management Board

**Management Courses Taken**

1992: Regional meetings on managed care within the National Health Service, Oxford  
 1992: Oxford Region Management course on managed health care, Oxford

## Teaching Service

[Key: \*S=School: Graduate School (GS); Medical School (MS)

\*\*L=Level: Undergraduate (U); Graduate (G); Postgraduate (P); Resident (R); Fellow (F)]

### Classroom/Laboratory

<i>Years</i>	<i>Course Description</i>	<i>S*/L**</i>	<i>Hours</i>	<i>Role</i>
<b><u>University of Texas – Houston Health Science Center</u></b>				
1993-1998	Mock examinations' tutor for U.S. Board exams in psychiatry	MS/R	4 h/month	Faculty tutor
1993-1998	Examiner for mock orals for residents in psychiatry preparing for the Board Examinations	MS/R	4 h/month	Faculty tutor
1994-1998	Teaching general medicine to residents in substance abuse as part of didactic lecture curriculum in preparation for Board Examinations.	MS/R	6 h/year	Faculty tutor
1994-1998	Psychopharmacology, neuroscience, neuroimaging	MS/G/P	4 h/week	Faculty tutor
1995-1997	Problem Based Learning (PBL) for medical students	MS/G	4 h/week	Faculty facilitator
1995-1998	Examiner for UT medical students final examinations	MS/G	10-12 h/year	Faculty examiner
1997-1998	Pharmacology	GS/P	4 h/year	Faculty tutor
1997-1998	Research methodology, basic psychopharmacology, and clinical research techniques open to staff	MS/P/R/ U	1.5 h/week	Faculty tutor
<b><u>The University of Texas Health Science Center at San Antonio</u></b>				
1998-2004	Substance Abuse Fellows Training Seminar on research methodology, basic psychopharmacology, and clinical research techniques	MS/P/R/U	1.5 h/week	Faculty tutor
1998-2004	Division Faculty Co-Investigator Seminar on methodology, basic psychopharmacology, and clinical research techniques	MS/Junior faculty	1.5 h/week	Seminar leader
2000-2004	Scheduled mentoring sessions in clinical aspects of substance abuse treatment	MS/F/ Faculty	0.5 h/week	Faculty tutor
<b><u>University of Virginia</u></b>				
2005-2013	Neuropharmacology	MS/G/R/F	1–2 h/week	Faculty tutor
2005-2013	Residents Training Course in Neuropsychopharmacology	MS/R	Monthly	Faculty tutor



2005-2013	Faculty Training Course in Neuropsychopharmacology	MS/F	Weekly	Faculty tutor
2006-2013	Neuroscience Graduate Program	MS/G		Faculty tutor; supervisor of graduate students

### **Clinical**

<i>Years</i>	<i>Setting</i>	<i>S*/L**</i>	<i>Weeks/Year</i>	<i>Hours/Week</i>
--------------	----------------	---------------	-------------------	-------------------

#### **University of Texas – Houston Health Science Center**

1993-1998	Residency teaching in substance abuse & pharmacology	MS/R	All academic year	4 hours/week
1993-1998	Medical student teaching: interview & seminar training	MS/G	All academic year	6-8 hours of teaching/week
1993-1998	Topic coordinator for research training in psychiatry for residents	MS/R	Four weeks/year	1.5 hours/week

#### **The University of Texas Health Science Center at San Antonio**

1999-2004	Clinical demonstrations for fellows, faculty, visiting scholars	MS/G	All academic year	4 hours/week
2000-2004	Specialist Seminars for Academic Development	MS/G	All academic year	4 hours/week

#### **University of Virginia**

2005-2013	Resident clinical teaching rounds	MS/R	Monthly	
2010- 2013	“How to Do It!” seminar series for residents	MS/R	Monthly	

### **Instructional Development**

#### **Formal Study to Improve Teaching Abilities**

1991: Communication and management skills training. King’s Fund College, London  
 1991-1993: Seminars and didactic teaching. Oxford University Department of Psychiatry  
 1995: Problem-based learning instructional seminars, University of Texas – Houston Health Science Center

#### **Research Concerning Teaching: Development of Curriculum or Teaching Materials, Methods, or Evaluation**

1993-1998	University of Texas – Houston Health Science Center Revision of didactic residency training curriculum as chairman of the Didactic Curriculum Committee. Revision of the curriculum was based on developing the course to be more focused towards the Board examinations, 1994.
1998-2004	The University of Texas Health Science Center at San Antonio

Ongoing development of curriculum for weekly didactic research training seminars for Junior Faculty, Addiction Residents, Research Fellows, and senior research staff members. Curriculum included sessions on current psychiatric and pharmacological

research, employing scientific method in clinical and human laboratory experimental design, journal article review, and grantsmanship.

### **Media and Software Developed**

- 1993-present Proprietary software for assessing human performance in the laboratory
- 1998 Johnson, B.A. & Thornton, J.: “SAFTEE Interview”. Training video for the National Institute on Alcohol Abuse and Alcoholism Project COMBINE, produced by The University of Texas Health Science Center at San Antonio.
- 1998 Brey, R., Johnson, B.A., Thornton, J. “Neurological Evaluation”. Training video for the National Institute on Alcohol Abuse and Alcoholism Project COMBINE, produced by The University of Texas Health Science Center at San Antonio.
- 2000 Johnson, B.A. “Mechanistic Hypothesis Explaining Ondansetron’s Treatment Effectiveness Among Biological Alcoholics”. Informational video, produced by The University of Texas Health Science Center at San Antonio, August 2000.

### **Teaching Materials**

- 1994 Understanding Research: A Guide for Residents. University of Texas – Houston Health Science Center (Johnson, B.A., Ed.).
- 1997 Problem Based Learning Teaching Materials for Psychiatry Residents. University of Texas – Houston Health Science Center (Johnson, B.A. and Roache, J.D., Eds.).

### **Ph.D. Dissertations Directed, Membership on Supervising Committees, Students and Postdoctoral Fellows Supervised, and Faculty Mentorship**

#### **Ph.D. Dissertations Directed**

- 2003-2006 Lynn Oswald, M.S.N., R.N. Assisted her Supervisor (John Roache, Ph.D.) (1998-2001).  
Natalia V. Sergeeva, B.A.

#### **Membership on Supervising Committees**

- 2001-2004 Lora Talley Watts, B.S.

#### **Rotation Students Supervised**

- 1999-2000 David Huang, B.S.

#### **Post-Doctoral Fellows Supervised and Junior Faculty Mentees**

- 1995-1997 Neera Khilnani, M.D.
- 1996-1997 Alex Shafer, Ph.D.
- 1996-1997 Debra Simms, Ph.D.
- 1996-1998 Patrick Bordnick, Ph.D.
- 1997-2013 Nassima Ait-Daoud Tiouririne, M.D.
- 2000-2002 Suzette Stoks, Ph.D. ()
- 2001-2002 Catherine Hoerster, Ph.D.
- 2001-2003 Tracy Sloan, Ph.D.
- 2001-2004 Michael Dawes, M.D.
- 2003-2004 Michael Worsley, Psy.D.
- 2003-2013 Chamindi Seneviratne, M.D.
- 2005-2008 Gabrielle Marzani-Nissen, M.D.
- 2006 Alison Breland, Ph.D.
- 2006-2008 David V. Hamilton, M.D.

2006-2008 J. Kim Penberthy, Ph.D.  
2006-2013 Wendy J. Lynch, Ph.D.  
2008-2013 Heather M. Haughey, Ph.D.  
2008-2013 Erik W. Gunderson, M.D.

**General Mentorship within the Division of Alcohol and Drug Addiction (The University of Texas Health Science Center at San Antonio)**

As part of my mentorship duties, I met division faculty on a bi-weekly basis to review their progress. Additionally, I held divisional meetings every eight weeks to facilitate divisional communication and strategic planning.

**General Mentorship within the Department of Psychiatry (The University of Texas Health Science Center at San Antonio)**

As part of my duties as Deputy Chairman for Research, I held regular meetings for junior and senior researchers in the Department to discuss challenges and opportunities and encourage further development of research programs at The University of Texas Health Science Center at San Antonio. I also conducted a series of presentations on research career development topics within the department.

**Media/Community Presentations**

This section is provided only as a summary to depict the major press releases and media appearances pertaining to my research.

1. Development of the dihydropyridine-class calcium channel antagonist, isradipine, as a preventative agent against cocaine-induced cerebral ischemia. Featured as “New Weapon Against Strokes” in the *New York Times*, Science Times Section - Health Watch, April 28, 1998 (page C7), and CNN Headline News Health Report aired on April 28, 1998. Multiple other national and local television, radio, and newspaper coverage on this discovery through 1999.
2. Development of serotonin-3 receptor antagonist, ondansetron, as a treatment for alcohol dependence, which was published in *JAMA* in August 2000. Media coverage included interviews and commentary to television, radio, Internet, and print media outlets worldwide, such as CNN, Fox, ABC, NBC, CBS, MSNBC, NPR, AP Radio Network, CBS Radio Network, Discovery.com, WebMD, Netscape, Yahoo, AOL, the *New York Times*, *Washington Post*, *USA Today*, *Time*, *Newsweek*, *U.S. News & World Report*, *Science News*, the Associated Press, Bloomberg News Service, Reuters, Canadian television, a Norwegian daily newspaper, Agence France-Press, and local San Antonio radio and TV coverage.
3. Development of the glutamate antagonist, topiramate, for the treatment of alcohol dependence, which was published in *The Lancet* in May 2003. Media coverage included interviews and commentary to television, radio, Internet, and print media outlets worldwide, such as CNN Headline News, Fox, ABC, NBC, BBC, CBS, MSNBC, NPR, AP Radio Network, CBS Radio Network, WebMD, AOL, Yahoo, CNN.com, Netscape, the *New York Times*, *Washington Post*, *Seattle Times*, the Associated Press, Bloomberg News Service, Reuters, and local San Antonio radio and TV coverage.
4. Renewed interest in the topiramate study following the publication of two secondary studies in *Archives of General Psychiatry* in 2004 and *Archives of Internal Medicine* in 2005, as well as the opening of the University of Virginia Center for Addiction Research and Education. Media coverage included both “All Things Considered” and “The Infinite Mind” on NPR, the NPR News Weekend Edition, articles in *The Wall Street Journal*, *The Chicago Sun-Times*, *The Philadelphia Daily News*, the *Richmond Times-Dispatch*, the *Dow Jones News Service*, and both

- the international and U.S. editions of *Newsweek*, and local television and radio broadcasts. *Wired News* continued the topiramate coverage with an article in April 2006.
5. In March 2007, a flurry of local and national television, radio, and print media coverage surrounding the inclusion — in the Home Box Office original documentary feature, “Addiction” — of a segment on my ongoing research on topiramate, along with profiles of two of my alcohol-dependent patients at UVa. In September 2007, “The Addiction Project” won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts & Sciences.
  6. Media interest in late 2007 following the publication of the multi-site topiramate study in October in *JAMA*. This was the largest such story in the history of UVa, with media coverage including Reuters, MSNBC, CBS, ABC, CNN, Fox News, the Associated Press, *USA Today*, *Scientific American*, *Neurology Reviews*, The Healthcare Channel (on <http://thehcc.tv/>), and local news organizations throughout the world. Additional media coverage — such as on BBC News and *U.S. News & World Report* — was generated by the publication of our second paper pertaining to the study in June 2008 in *Archives of Internal Medicine*.
  7. On April 18 and 19, 2009, an appearance in the *CNN Presents* documentary special titled “Addiction: Life on the Edge”. Dr. Sanjay Gupta, CNN’s chief medical correspondent, had interviewed me in 2008, and this segment aired during the portion of the program that pertained to medications for treating alcoholism.
  8. Media interest in January and February 2011 following the publication of the study on the pharmacogenetic treatment of alcoholism in *The American Journal of Psychiatry*. This included a piece in *JAMA Medical News*, as well as inclusion in an article about research on molecular pharmacogenetics for alcoholism treatment that appeared in *The Wall Street Journal* (and was highlighted on the front page) on February 8, 2011.
  9. On May 22, 2011, an appearance and interview on the *Dr. Sanjay Gupta Reports* documentary on CNN titled “Patrick Kennedy — Coming Clean”, which focused on the former Congressman’s struggle with addiction.
  10. An interview for the article by Katherine Harmon titled “Does Rehab Work as a Treatment for Alcoholism and Other Addictions?” in the July 25, 2011 issue of *Scientific American*.
  11. An interview on NPR’s “Talk of the Nation” program titled “What We Are Learning About Alcohol”, on January 16, 2012. The recent CDC report titled “Binge Drinking: Nationwide Problem, Local Solutions” was discussed.
  12. An interview and inclusion in a *New York Times* article titled “Drugs Help Tailor Alcoholism Treatment” that appeared on page D1 of the New York edition on May 22, 2012.
  13. In advance of the publication on a multi-site trial of topiramate for the treatment of methamphetamine addiction in July 2012 in *Addiction*, I was interviewed on WINA News Radio, on WCAV Newsplex “CBS 19” (television station), and for an article in *The Daily Progress* (newspaper), all based in Charlottesville, Virginia, in June 2012.
  14. Mentioned in *The Baltimore Sun* article, “UM medical school opens brain research unit,” by Andrea K. Walker, published on February 12, 2014. [http://articles.baltimoresun.com/2014-02-12/health/bal-umsm-brain-center\\_1\\_um-medical-school-new-unit-scientists](http://articles.baltimoresun.com/2014-02-12/health/bal-umsm-brain-center_1_um-medical-school-new-unit-scientists)
  15. A guest on the “Your Health” segment of Direct Connection with Jeff Salkin on Maryland Public Television. Description of the research on addiction, references to the SOM Brain Science Consortium. Link: <http://video.mpt.tv/video/2365199268/>, in Baltimore, Maryland; March 10, 2014.
  16. Interview by Kathy Gould for PBS NewsHour: The STEM Profile Projects. <http://www.pbs.org/newshour/extra/2014/04/the-stories-behind-22-stem-superstars/>

17. A guest on The Diane Rehm Show – New Ways of Treating Alcoholism. Link: <http://thedianerehmshow.org/shows/2014-07-14/new-ways-treating-alcoholism>  
WAMU 4401 Connecticut Ave, NW, DC, July 14, 2014.
18. Interview by Kathleen Patchan, MD, for the Maryland Psychiatrist newsletter. New Chair at UMMS; Professor Bankole Johnson, DSc, MD, Winter 2015, pp 4-7.
19. An interview and inclusion in *The Huffington Post* article, titled “Dying To Be Free,” by Jason Cherkis, published on January 28, 2015. <http://projects.huffingtonpost.com/dying-to-be-free-heroin-treatment>
20. An interview and inclusion in a Healthline News article, “Cheaper Antipsychotics Save Money, but Prescribed Against Guidelines for Children,” by Brain Krans, published on August 22, 2015. <http://www.healthline.com/health-news/cheaper-antipsychotics-save-money-but-prescribed-against-guidelines-for-children-082215#2>
21. A featured interview for *The Washington Post* article, “To break heroin addiction, one neuroscientist suggests using drugs,” by Courtland Milloy, published on December 15, 2015. [https://www.washingtonpost.com/local/to-break-heroin-addiction-one-neuroscientist-suggests-using-drugs/2015/12/15/6cc82290-a35b-11e5-9c4e-be37f66848bb\\_story.html?hpid=hp\\_regional-hp-cards\\_regional-card-columnists:homepage/card](https://www.washingtonpost.com/local/to-break-heroin-addiction-one-neuroscientist-suggests-using-drugs/2015/12/15/6cc82290-a35b-11e5-9c4e-be37f66848bb_story.html?hpid=hp_regional-hp-cards_regional-card-columnists:homepage/card)
22. An inclusion and quote in *The Huffington Post* article, titled “A Maryland Lawmaker Offers A Radical New Solution To The Heroin Crisis,” by Jason Grim, published on February 4, 2016. [http://www.huffingtonpost.com/entry/dan-morhaim-heroin\\_us\\_56b3c342e4b08069c7a69b86](http://www.huffingtonpost.com/entry/dan-morhaim-heroin_us_56b3c342e4b08069c7a69b86)
23. Mentioned in *The Baltimore Sun*, in the article, “Two Baltimore-area lawmakers propose decriminalizing small amounts of all drugs, safe injection facilities,” by Kevin Rector, published on February 5, 2016, <http://www.baltimoresun.com/news/maryland/politics/bs-md-morhaim-drug-bills-20160205-story.html>.
24. Interviewed by NBC Washington (DC affiliate) for the special report, “Generation Addicted,” which aired and was published on March 22, 2016. The Generation Addicted feature links to all components of the project, <http://data.nbcstations.com/national/2016/PHI/addiction/index.html>; and was included in the documentary, <http://data.nbcstations.com/national/2016/PHI/addiction/index.html?story=33>, and the piece entitled, “Q&A: Addiction Docs Provide Insight.”
25. Quoted in “A Maryland Delegate proposes bills for pilot heroin and opioid maintenance programs to tackle the state’s drug epidemic” in *City Paper*, <http://www.citypaper.com/news/features/bcp-040616-feature-heroin-legal-20160406-story.html>, published on April 6, 2016.
26. Quoted in “Side effects from Chantix rare, should not discourage people from quitting smoking, experts say,” in the *Carroll County Times*, <http://www.carrollcountytimes.com/news/health/ph-cc-chantix-sidebar-20160808-story.html>, published on August 9, 2016.
27. Interviewed by Harold Reitman, MD, for Different Brains: The Neurodiversity Community for All of Us, in “Neurodiversity and Addiction: An Interview with Professor Bankole A. Johnson of HBO’s “Addiction” Series,” published on November 10, 2016, <http://differentbrains.com/neurodiversity-overcoming-addiction-interview-dr-bankole-johnson/>.
28. Interviewed by MedPage Today for the special report, “What the Surgeon General’s Addiction Report Really Means: Addiction and pain experts discuss landmark report,” which was published on November 18, 2016: <http://www.medpagetoday.com/psychiatry/addictions/61554>.
29. Quoted in *The Baltimore sun* in “Research offers mixed messages on the impact of social media on adolescent emotional health,” published on June 2, 2017: <http://www.baltimoresun.com/health/bs-hs-social-media-teens-20170526-story.html>.

30. Interviewed and quoted in The Baltimore Sun for the article, “Scientists explore drug’s value in treating both alcoholism and PTSD,” published on November 20, 2017:  
<http://www.baltimoresun.com/health/bs-hs-drug-for-alcoholism-20171120-story.html>.
31. Featured in The Doctors Channel in “Pharmacogenetic Approach to Treating Alcohol Use Disorder,” published on January 10, 2019.  
<https://www.thedoctorschannel.com/view/pharmacogenetic-approach-to-treating-alcohol-use-disorder/>.

## **Grant Support**

### **Active Grants**

- 2/10/18-1/31/23 Bankole Johnson, Chamindi Seneviratne  
 “Genomic Predictors of Placebo Response in Phase II AUD Trials”  
 NIAAA 1R01AA026291-01  
 Total Amount: \$2,857,615
- 4/15/16-3/31/21 Bankole Johnson, Melanie E. Bennett  
 “Pharmacogenetic Treatment with Anti-Glutaminergic Agents for Comorbid PTSD & AUD”  
 NIAAA 1R01AA024760-01  
 Total Amount: \$2,867,635

### **Completed Grants**

- 1991-1993 Bankole Johnson (PI)  
 “Research Scientist Development Award to Study the Effects of the 5-HT3 Antagonist, Ondansetron, on the Rewarding Effects of Alcohol”  
 Wellcome Research Foundation  
 Direct Costs/Current Year/Total: \$100,000
- 1993-1995 Bankole Johnson (Co-Inv)  
 “New Medications for Cocaine and Opiate Dependence”  
 NIDA  
 Projected Total Amount for Entire Range of Years: \$1,626,325
- 1993-1995 Bankole Johnson (Co-Inv)  
 “Patient Methadone S.A.: Behavioral Pharmacological Analysis”  
 NIDA  
 Projected Total Amount for Entire Range of Years: \$117,376
- 1994-1995 Bankole Johnson (PI)  
 “Ritanserlin in the Treatment of Cocaine Dependence”  
 Janssen Pharmaceuticals  
 Direct Costs/Current Year/Total: \$390,000
- 1994-1995 Bankole Johnson (PI)  
 “Ritanserlin in the Treatment of Alcohol Dependence”  
 Janssen Pharmaceuticals  
 Direct Costs/Current Year/Total: \$360,000
- 1994-1998 Bankole Johnson (Co-Inv)  
 “Drug Effects on Alcohol Reinforcement in Rhesus Monkeys”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$510,316

1994-1999 Bankole Johnson (Co-Inv)  
 “Ritanserin and Relapse Prevention for Cocaine Dependence”  
 NIDA  
 Projected Total Amount for Entire Range of Years: \$949,051

1995-1996 Bankole Johnson (PI)  
 “Ritanserin in the Treatment of Alcohol Dependence – An Extension Study”  
 Janssen Pharmaceuticals  
 Direct Costs/Current Year/Total: \$60,000

1995-2000 Bankole Johnson (PI)  
 “Pharmacological Treatments for Alcoholism”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$1,759,369

1996-1998 Bankole Johnson (PI)  
 Unrestricted Educational Grant  
 Glaxo Wellcome Pharmaceuticals  
 Direct Costs/Current Year/Total: \$180,000

1996-1998 Bankole Johnson (PI)  
 “A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects with Schizophrenia and Schizoaffective Disorders”  
 Janssen Pharmaceuticals  
 Direct Costs/Current Year/Total: \$368,000

1996-1998 Bankole Johnson (PI)  
 “SPECT Studies of Cocaine Dependent Patients”  
 Advanced Technology Program (ATP) Texas Higher Education Coordinating Board  
 Direct Costs/Current Year/Total: \$130,216

1997 Bankole Johnson (Sponsor)  
 “Identification of Uniquely Expressed Transcripts Among Alcohol Abusers by RNA Fingerprinting”  
 Operational Program for Industrial Development – Graduate Training Program in RTCs  
 Direct Costs/Current Year/Total: \$16,504

1997-1999 Bankole Johnson (PI)  
 “SPECT Studies of Cocaine Dependent Subjects”  
 NIDA

1997-2003 Bankole Johnson (PI)  
 “Joint Behavioral/Pharmacologic Treatment of Alcoholism (COMBINE)”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: Approx. \$3 million

1998-2000 Bankole Johnson (Sponsor/Mentor)  
 Minority supplement for Dr. Nassima Tiouririne, appended to “Pharmacological Treatments of Alcoholism”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$136,432

1998-2001 Bankole Johnson (PI)  
 “Topiramate for the Treatment of Alcohol Dependence”



Ortho-McNeil Pharmaceutical, Inc.  
 Direct Costs/Current Year/Total: \$237,500  
 1999-2000 Bankole Johnson (PI)  
 Administrative supplement for training minority researchers from Howard University, appended to “Pharmacological Treatments of Alcoholism”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$128,490  
 1999-2000 Bankole Johnson (PI)  
 Unrestricted Educational Grant  
 Janssen Pharmaceuticals  
 Direct Costs/Current Year/Total: \$5,000  
 1999-2001 Bankole Johnson (PI)  
 “Multicenter Safety Trial of Buprenorphine/Naloxone for Office-Based Treatment of Opiate Dependence”  
 NIDA/VA  
 Projected Total Amount for Entire Range of Years: \$241,501  
 “Genotyping for Subtypes of Alcoholic by Treatment Response”  
 Texas Commission on Alcohol and Drug Abuse/Waggoner Center for Alcohol and Addiction Research at the University of Texas at Austin  
 Direct Costs/Current Year/Total: \$292,000  
 1999-2003 Bankole Johnson (PI)  
 “Lab Trials to Develop Medications for Cocaine Dependence”  
 NIDA  
 Projected Total Amount for Entire Range of Years: \$1,048,497  
 1999-2005 Bankole Johnson (PI)  
 “Cocaine Brain Effects and Neuroimaging”  
 NIDA  
 Projected Total Amount for Entire Range of Years: \$1,091,289  
 1999-unknown Bankole Johnson (Co-I)  
 “Clinical Trials Operations”  
 NIDA  
 Projected Amount: Task Order Contract for estimated \$450,000/year  
 2000 Bankole Johnson (PI)  
 “Collaborative Research Projects on Alcohol Treatment”  
 NIAAA  
 Total Amount: \$243,600  
 2000-2001 Bankole Johnson (PI)  
 Administrative supplement for training minority researchers from Howard University, appended to “Pharmacological Treatments of Alcoholism”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$144,000  
 2000-2001 Bankole Johnson (PI)  
 “CPH-101 in Heavy Alcohol Drinkers with Impaired Control. A 12 + 40 Week Placebo Controlled Dose Response Study”  
 Oryzalis Pharma, Ltd.  
 Direct Costs/Current Year/Total: \$433,800

2000-2001 Bankole Johnson (PI)  
 “Naltrel 99-03: Safety and Efficacy of Naltrel in Treatment of Alcohol Dependence”  
 Quintiles  
 Direct Costs/Current Year/Total: \$131,500

2000-2001 Bankole Johnson (PI)  
 “A Phase 1b Evaluation of the Safety and Pharmacokinetics of Repeat Dose Administration of Medisorb® Naltrexone in Alcohol Dependent Patients”  
 Alkermes, Inc.  
 Direct Costs/Current Year/Total: \$118,701

2000-2004 Bankole Johnson (PI)  
 “Medication Development for Methamphetamine Dependence”  
 NIDA  
 Total Amount for First Year Only: \$293,066

2000-2005 Bankole Johnson (PI)  
 “Combining Pharmacologic Treatments for Alcoholism”  
 NIAAA  
 Projected Total Amount for Entire Range of Years: \$3,374,692

2000-2008 Bankole Johnson (PI)  
 “Pharmacologic Treatments for Alcoholism – Continuation”  
 NIAAA  
 Total Amount for First Year Only: \$784,862

2001-2003 Bankole Johnson (PI)  
 “Making a Difference in Adolescent Alcoholism Prevention and Treatment”  
 Goldsbury Foundation  
 Direct Costs/Current Year/Total: \$1,000,000

2001-2010 Bankole Johnson (PI)  
 “Combined Pharmacotherapies for Alcoholism”  
 NIAAA  
 Total Amount for First Year Only: \$674,845

2002-2003 Bankole Johnson (PI)  
 “A Phase III Multi-Center, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol Dependent Adults”  
 Alkermes, Inc.  
 Direct Costs/Current Year/Total: \$172,792

2002-2004 Bankole Johnson (Co-I)  
 “Construction of Addiction Research Center”  
 NIH, Department of Health and Human Services (DHHS) 1 C06 RR15517-01A1  
 Projected Total Amount for Entire Range of Years: \$2,996,175

2002-2005 Bankole Johnson (PI)  
 “Combined Pharmacotherapies for Alcoholism & Pharmacologic Treatments for Alcoholism”  
 GlaxoSmithKline  
 Direct Costs/Current Year/Total: \$76,350

2003-2007 Bankole Johnson (PI)  
 “Joint Behavioral/Pharmacologic Treatment of Alcoholism (COMBINE) – Extension”  
 NIAAA  
 Total Amount for First Year Only: \$445,294

2003-2009 Bankole Johnson (PI)  
 “Lab Trials to Develop Medications for Cocaine Dependence – Extension”  
 NIDA  
 Total Amount for First Year Only: \$390,962

2004 Bankole Johnson (PI)  
 “Topiramate for the Treatment of Cocaine Dependence”  
 Ortho-McNeil Pharmaceutical, Inc.  
 Direct Costs/Current Year/Total: \$99,898

2004 Bankole Johnson (PI)  
 “A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence from Alcohol in Subjects with Alcoholism”  
 Bristol-Myers Squibb  
 Direct Costs/Current Year/Total: \$239,286

2004-2006 Bankole Johnson (PI)  
 “A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence”  
 Ortho-McNeil Pharmaceutical, Inc.  
 Direct Costs/Current Year/Total: \$190,000

2004-2010 Bankole Johnson (PI)  
 “New Medications to Treat Alcohol Dependence”  
 NIAAA  
 Total Amount for First Year Only: \$344,057

2004-2012 Bankole Johnson (PI)  
 “Combining Medication Treatments for Alcoholism”  
 NIAAA  
 Total Amount for First Year Only: \$638,283

2005-2007 Bankole Johnson (Lead Investigator)  
 “Phase 2, Double-Blind, Placebo-Controlled Trial of Topiramate for the Treatment of Methamphetamine Dependence”  
 NIDA  
 Projected Total Amount for Entire Range of Years: Approx. \$3 million

2005-2011 Bankole Johnson (PI)  
 “Medication Development for Cocaine Dependence”  
 NIDA  
 Total Amount for First Year Only: \$624,015

2005-2012 Bankole Johnson (PI)  
 “Novel Pharmacotherapy for Dual Dependence”  
 NIDA  
 Total Amount for First Year Only: \$524,890

2006-2007 Bankole Johnson (PI)

2006-2009 “Double-Blind, Placebo-Controlled Multicenter Trial of Quetiapine for the Treatment of Alcohol Dependence”  
AstraZeneca Pharmaceuticals LP  
Direct Costs/Current Year/Total: \$47,854  
Bankole Johnson (PI)

2007-2009 “Double-Blind, Placebo-Controlled Multisite Trial of Quetiapine for the Treatment of Alcohol Dependence”  
NIAAA  
Projected Total Amount for Entire Range of Years: \$820,000  
Bankole Johnson (PI)

2007-2013 “Ondansetron with Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial”  
TransOral Pharmaceuticals, Inc. / Transcept Pharmaceuticals, Inc.  
Direct Costs/Current Year/Total: \$656,770  
Bankole Johnson (Co-I), Nassima Ait-Daoud (PI)

2008-2013 “New Medication Treatments for Stimulant Dependence”  
NIDA 5R01DA021776  
Total Amount: \$2,644,262  
Bankole Johnson (PI)

2008-2014 “Lab Trials to Develop Medications for Cocaine Dependence Study 1”  
NIDA 5M01RR000847  
Total Amount for 2010: \$825,906  
Bankole Johnson (Co-I), Wendy Lynch (PI)

2008-2017 “Rat Models of Alcohol Dependence for Evaluating Combined Medication Effects”  
NIAAA 5R01AA016554  
Total Amount : \$1,568,637  
Bankole Johnson (PI)

2009-2012 “Pharmacologic Treatments in Emerging Adults”  
NIAAA 5R01AA010522  
Total Amount for 2012: \$663,655; for 2011: \$664,220  
Bankole Johnson (Co-I)

2009-2012 “Medications Development for the Treatment of Cannabis Related Disorders”  
NIDA  
Total Amount for First Year Only: \$345,333  
Lei Liu, Bankole Johnson, and John O’Quigley (Co-PIs)

2010-2016 “Innovative Analytic Methods of Person-Centered Data and Adaptive Designs for Alcohol Treatment Research”  
NIAAA 5RC1AA019274  
Total Amount for 2010: \$334,448  
Nassima Ait-Daoud, Bankole Johnson, Robert Anthenelli, and Paul Cinciripini (Co-PIs)

2012-2017 “New Pharmacotherapy for Alcohol and Co-Morbid Disorders”  
NIAAA 5R01AA019720  
Total Amount for 2014: \$827,356; for 2013: \$806,997  
Bankole Johnson, Nassima Ait-Daoud, and Ming Li (Co-PIs)

“Pharmacogenetic Treatments for Alcoholism”

2013-2014 NIAAA 1R01AA021163  
Total Amount for 2012: \$543,690  
Bankole Johnson (PI)  
“NCIG-004, A Phase 2, Double-Blind, Randomized, Placebo Controlled  
Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence”  
Fast-Track Drugs and Biologics, LLC

### **Patents, Inventions and Copyrights**

Johnson, Bankole A.: Patent No 2255184 [Austria, Belgium, Switzerland, Czech Republic, Denmark, European, Spain, Finland, France, United Kingdom, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Rep of Macedonia, Malta, Netherlands, Poland, Sweden, Slovenia, Slovakia, Turkey. “Serotonin transporter gene and treatment of alcoholism”. Issued April 24, 2013.

Johnson, Bankole A.: No 602009015213.0, Germany. “Serotonin transporter gene and treatment of alcoholism”. Issued April 24, 2013.

Johnson, Bankole A.: Patent No P20130621, Croatia. “Serotonin transporter gene and treatment of alcoholism”. Issued April 24, 2013.

Johnson, Bankole A.: Patent No 588037, New Zealand. “Serotonin transporter gene and treatment of alcoholism”. Issued December 11, 2012.

### **Publications**

**h-index: 66**

**Citation index: 15,631**

### **Peer-Reviewed Journal Articles**

1. Johnson, B.A.: Toxicity of lofepramine in heart disease. Irish Journal of Psychological Medicine 7 (2): 142-143, 1990.
2. Johnson, B.A., Campbell, L.B.: Mood disorder, ‘pre-ictal’ psychosis and temporal lobe damage. British Journal of Psychiatry 157: 441-444, 1990.
3. Johnson, B.A.: Psychopharmacological effects of cannabis. British Journal of Hospital Medicine 43 (2): 114-122, 1990.
4. Johnson, B.A.: Substance misuse among psychiatric hospital in-patients. Irish Journal of Psychological Medicine 7 (2): 114-117, 1990.
5. Sharpe, M.C., Johnson, B.A., McCann, J.: Mania and recovery from chronic fatigue syndrome. Journal of the Royal Society of Medicine 84 (1): 51-52, 1991.
6. Johnson, B.A., Cowen, P.J.: Calcium channel blockade and resistant bipolar depression. Irish Journal of Psychological Medicine 8: 50-51, 1991.
7. Silverstone, P.H., Johnson, B., Cowen, P.J.: Does ondansetron attenuate amphetamine-induced behaviour in human volunteers? Psychopharmacology 107 (1): 140-141, 1992.
8. Silverstone, P.H., Oldman, D., Johnson, B., Cowen, P.J.: Ondansetron, a 5-HT<sub>3</sub> receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. International Clinical Psychopharmacology 7 (1): 37-43, 1992.

9. Johnson, B.A., Wells, L.T.: Computers in psychiatry. 1. Basics and purchasing tips. *Psychiatric Bulletin* 16 (11): 703-708, 1992.
10. Johnson, B.A., Wells, L.T.: Computers in psychiatry. 2. Viruses — prevention, detection, and removal. *Psychiatric Bulletin* 16 (12): 771-773, 1992.
11. Johnson, B.A., Campling, G.M., Griffiths, P., Cowen, P.J.: Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT<sub>3</sub> receptor blockade: a preliminary study in healthy male volunteers. *Psychopharmacology* 112 (1): 142-144, 1993.
12. Johnson, B.A., Rue, J., Cowen, P.J.: Ondansetron and alcohol pharmacokinetics. *Psychopharmacology* 112 (1): 145, 1993.
13. Johnson, B.A.: Computers in psychiatry. 3. Introduction to electronic telecommunication. *Psychiatric Bulletin* 17 (1): 42-43, 1993.
14. Johnson, B.A.: Computers in psychiatry. 4. On artificial intelligence (AI): is there a ghost in the machine? *Psychiatric Bulletin* 17 (2): 100-103, 1993.
15. Johnson, B.A., Cowen, P.J.: Alcohol-induced reinforcement: dopamine and 5-HT<sub>3</sub> receptor interactions in animals and humans. *Drug Development Research* 30 (3): 153-169, 1993.
16. Johnson, B.A.: The Maudsley's obsessional children: phenomenology, classification, and associated neurobiological and co-morbid features. *European Child and Adolescent Psychiatry* 2 (4): 192-204, 1993.
17. Pether, R.G., Johnson, B.A., O'Donoghue, G., Connolly, J.: Psychiatrists' letters to general practitioners: choosing the right format. *Psychiatric Bulletin* 17: 414-415, 1993.
18. Johnson, B.A., Oldman, D., Goodall, E.M., Chen, Y.R., Cowen, P.J.: Effects of GR 68755 on d-amphetamine-induced changes in mood, cognitive performance, appetite, food preference, and caloric and macronutrient intake in humans. *Behavioral Pharmacology* 7 (3): 216-227, 1996.
19. Johnson, B.A., Jasinski, D.R., Galloway, G.P., Kranzler, H., Weinreb, R., Anton, R.F., Mason, B.J., Bohn, M.J., Pettinati, H.M., Rawson, R., Clyde, C.: Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial. Ritanserin Study Group. *Psychopharmacology* 128 (2): 206-215, 1996.
20. Johnson, B.A., Chen, Y.R., Swann, A.C., Schmitz, J., Lesser, J., Ruiz, P., Johnson, P., Clyde, C.: Ritanserin in the treatment of cocaine dependence. *Biological Psychiatry* 42 (10): 932-940, 1997.
21. Johnson, B.A., Lamki, L., Barron, B., Spiga, R., Chen, R., Meisch, R., Khilnani, N.: Brain blood flow abnormalities associated with oral cocaine use. *Irish Journal of Psychological Medicine* 14 (2): 72-73, 1997.
22. Johnson, B.A., Chen, Y.R., Schmitz, J., Bordnick, P., Shafer, A.: Cue reactivity in cocaine-dependent subjects: effects of cue type and cue modality. *Addictive Behaviors* 23 (1): 7-15, 1998.
23. Johnson, B., Lamki, L., Fang, B., Barron, B., Wagner, L., Wells, L., Kenny, P., Overton, D., Dhother, S., Abramson, D., Chen, R., Kramer, L.: Demonstration of dose-dependent global and regional cocaine-induced reductions in brain blood flow using a novel approach to quantitative single photon emission computerized tomography. *Neuropsychopharmacology* 18 (5): 377-384, 1998.
24. Johnson, B., Barron, B., Fang, B., Lamki, L., Wagner, L., Wells, L., Kenny, P., Overton, D., Dhother, S., Abramson, D., Chen, R., Kramer, L.: Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study. *Psychopharmacology* 136 (4): 335-341, 1998.
25. Johnson, B., Overton, D., Wells, L., Kenny, P., Abramson, D., Dhother, S., Chen, Y.R., Bordnick, P.: Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts. *Psychiatry Research* 77 (1): 35-42, 1998.

26. Chen, Y.R., Swann, A.C., Johnson, B.A.: Stability of diagnosis in bipolar disorder. *The Journal of Nervous and Mental Disease* 186 (1): 17-23, 1998.
27. Boyle, A.E.L., Stewart, R.B., Macenski, M.J., Spiga, R., Johnson, B.A., Meisch, R.A.: Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys. *Alcoholism: Clinical and Experimental Research* 22 (2): 359-366, 1998.
28. Johnson, B.A.: Comment on 'Health aspects of cannabis: revisited' (Hollister). *The International Journal of Neuropsychopharmacology* 1 (1): 81-82, 1998.
29. Johnson, B., Wells, L., Kenny, P., Abramson, D., Chen, R., Dhoother, S., Overton, D., Bordnick, P.: Effects of isradipine on intravenous cocaine-induced cardiovascular response: a pilot study. *Human Psychopharmacology - Clinical and Experimental* 14: 37-43, 1999.
30. Ruiz, P., Varner, R.V., Small, D.R., Johnson, B.A.: Ethnic differences in the neuroleptic treatment of schizophrenia. *Psychiatric Quarterly* 70 (2): 163-172, 1999.
31. Swann, A.C., Johnson, B.A., Cloninger, C.R., Chen, Y.R.: Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: a preliminary study. *Psychopharmacology* 143 (4): 380-384, 1999.
32. Johnson, B.A., Roache, J.D., Bordnick, P.S., Ait-Daoud, N.: Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. *Psychopharmacology* 144 (3): 295-300, 1999.
33. Johnson, B.A., Ait-Daoud, N., Bordnick, P.S.: Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced reduction in hunger. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 23 (7): 1227-1234, 1999.
34. Johnson, B.A., Ait-Daoud, N.: Medications to treat alcoholism. *Alcohol Research & Health* 23 (2): 99-106, 1999.
35. Johnson, B.A., Cloninger, C.R., Roache, J.D., Bordnick, P.S., Ruiz, P.: Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. *The American Journal on Addictions* 9 (1): 17-27, 2000.
36. Johnson, B.A., Ait-Daoud, N., Wells, L.T.: Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced cognitive and physiological changes in humans. *Neuropsychopharmacology* 22 (5): 504-512, 2000.
37. Johnson, B.A., Ait-Daoud, N.: Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. *Psychopharmacology* 149 (4): 327-344, 2000.
38. Johnson, B.A., Ait-Daoud, N., Prihoda, T.J.: Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. *Alcoholism: Clinical and Experimental Research* 24 (5): 737-742, 2000.
39. Johnson, B.A., Roache, J.D., Javors, M.A., DiClemente, C.C., Cloninger, C.R., Prihoda, T.J., Bordnick, P.S., Ait-Daoud, N., Hensler, J.: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. *JAMA: The Journal of the American Medical Association* 284 (8): 963-971, 2000.
40. Johnson, B.A.: Serotonergic agents and alcoholism treatment: rebirth of the subtype concept – an hypothesis. *Alcoholism: Clinical and Experimental Research* 24 (10): 1597-1601, 2000.
41. Ait-Daoud, N., Johnson, B.A., Prihoda, T.J., Hargita, I.D.: Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. *Psychopharmacology* 154 (1): 23-27, 2001.
42. Ait-Daoud, N., Johnson, B.A., Javors, M., Roache, J.D., Zanca, N.A.: Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. *Alcoholism: Clinical and Experimental Research* 25 (6): 847-849, 2001.

43. Johnson, B.A., Devous, M.D., Sr., Ruiz, P., Ait-Daoud, N.: Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. *The American Journal of Psychiatry* 158 (8): 1191-1198, 2001.
44. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Zanca, N.A., Velazquez, M.: Ondansetron reduces the craving of biologically predisposed alcoholics. *Psychopharmacology* 160 (4): 408-413, 2002.
45. Ait-Daoud, N., Johnson, B.A.: Ondansetron with and without naltrexone as a treatment of biologic alcoholism: concepts and updated findings. *Addictive Disorders & Their Treatment* 1 (3): 75-80, 2002.
46. Enoch, M.-A., Schuckit, M.A., Johnson, B.A., Goldman, D.: Genetics of alcoholism using intermediate phenotypes. *Alcoholism: Clinical and Experimental Research* 27 (2): 169-176, 2003.
47. Johnson, B.A., O'Malley, S.S., Ciraulo, D.A., Roache, J.D., Chambers, R.A., Sarid-Segal, O., Couper, D.: Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprostate, both alone and combined, in alcohol-dependent subjects. *Journal of Clinical Psychopharmacology* 23 (3): 281-293, 2003.
48. Johnson, B.A., Ait-Daoud, N., Bowden, C.L., DiClemente, C.C., Roache, J.D., Lawson, K., Javors, M.A., Ma, J.Z.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. *The Lancet* 361 (9370): 1677-1685, 2003.
49. The COMBINE Study Research Group: Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. *Alcoholism: Clinical and Experimental Research* 27 (7): 1107-1122, 2003.
50. The COMBINE Study Research Group: Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): a pilot feasibility study. *Alcoholism: Clinical and Experimental Research* 27 (7): 1123-1131, 2003.
51. Sloan, T.B., Roache, J.D., Johnson, B.A.: The role of anxiety in predicting drinking behaviour. *Alcohol and Alcoholism* 38 (4): 360-363, 2003.
52. Johnson, B.A.: The role of serotonergic agents as treatments for alcoholism. *Drugs of Today* 39 (9): 665-672, 2003.
53. Javors, M.A., Johnson, B.A.: Current status of carbohydrate deficient transferrin, total serum sialic acid, sialic acid index of apolipoprotein J and serum  $\beta$ -hexosaminidase as markers for alcohol consumption. *Addiction* 98 (suppl 2): 45-50, 2003.
54. Johnson, B.A., Ait-Daoud, N., Ma, J.Z., Wang, Y.: Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. *Alcoholism: Clinical and Experimental Research* 27 (11): 1773-1779, 2003.
55. McBride, W.J., Lovinger, D.M., Machu, T., Thielen, R.J., Rodd, Z.A., Murphy, J.M., Roache, J.D., Johnson, B.A.: Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. *Alcoholism: Clinical and Experimental Research* 28 (2): 257-267, 2004.
56. Johnson, B.A., Swift, R.M., Ait-Daoud, N., DiClemente, C.C., Javors, M.A., Malcolm, R.J., Jr.: Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. *Alcoholism: Clinical and Experimental Research* 28 (2): 295-301, 2004.
57. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wells, L.T., Mauldin, J.B.: Effects of isradipine on cocaine-induced subjective mood. *Journal of Clinical Psychopharmacology* 24 (2): 180-191, 2004.
58. Dawes, M.A., Johnson, B.A.: Pharmacotherapeutic trials in adolescent alcohol use disorders: opportunities and challenges. *Alcohol and Alcoholism* 39 (3): 166-177, 2004.
59. Johnson, B.A.: The biologic basis of alcohol dependence. *Advanced Studies in Nursing* 2 (2): 48-53, 2004.



60. Lam, Y.-W.F., Javors, M.A., Ait-Daoud, N., Roache, J.D., Johnson, B.A.: Relative bioavailability of an extemporaneous 4 mg ondansetron capsule versus solution. *Pharmacotherapy* 24 (4): 477-481, 2004.
61. Kranzler, H.R., Wesson, D.R., Billot, L., Drug Abuse Sciences Naltrexone Depot Study Group: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research* 28 (7): 1051-1059, 2004.
62. Anton, R.F., Pettinati, H., Zweben, A., Kranzler, H.R., Johnson, B., Bohn, M.J., McCaul, M.E., Anthenelli, R., Salloum, I., Galloway, G., Garbutt, J., Swift, R., Gastfriend, D., Kallio, A., Karhuvaara, S.: A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. *Journal of Clinical Psychopharmacology* 24 (4): 421-428, 2004.
63. Littleton, J.M., De Witte, P., Litten, R., Gessa, G.L., Spanagel, R., Kranzler, H., Lehert, P., Johnson, B., Saunders, J., Berglund, M., Harris, A., Anton, R., Mann, K.: Challenges to medications development in treating alcohol dependence: an international perspective. Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003. *Alcohol and Alcoholism* 39 (4): 271-275, 2004.
64. Johnson, B.A.: Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. *Alcoholism: Clinical and Experimental Research* 28 (8): 1137-1144, 2004.
65. Johnson, B.A.: Uses of topiramate in the treatment of alcohol dependence. *Expert Review of Neurotherapeutics* 4 (5): 751-758, 2004.
66. Johnson, B.A.: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of co-morbid alcohol and nicotine dependence? *Addictive Behaviors* 29 (7): 1465-1479, 2004.
67. Johnson, B.A., Ait-Daoud, N., Akhtar, F.Z., Ma, J.Z.: Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. *Archives of General Psychiatry* 61 (9): 905-912, 2004.
68. Johnson, B.A.: An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. *Expert Opinion on Pharmacotherapy* 5 (9): 1943-1955, 2004.
69. Johnson, B.A., Ait-Daoud, N., Aubin, H.-J., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., Ehrich, E.: A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence. *Alcoholism: Clinical and Experimental Research* 28 (9): 1356-1361, 2004.
70. Johnson, B.A.: Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. *CNS Drugs* 18 (15): 1105-1118, 2004.
71. Johnson, B.A.: Bankole A. Johnson interview. *Lancet* 17;363(9404):256, January 2004. (PMID 14738827).
72. Javors, M.A., Seneviratne, C., Roache, J.D., Ait-Daoud, N., Bergeson, S.E., Walss-Bass, M.C., Akhtar, F.Z., Johnson, B.A.: Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 29 (1): 7-13, 2005.
73. Johnson, B.A., Javors, M.A., Lam, Y.-W.F., Wells, L.T., Tiouririne, M., Roache, J.D., Ait-Daoud, N., Lawson, K.: Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 29 (1): 15-20, 2005.
74. Raisch, D.W., Fudala, P.J., Saxon, A.J., Walsh, R., Casadonte, P., Ling, W., Johnson, B.A., Malkernek, U., Ordorica, P., Williford, W.O., Sather, M.R.: Pharmacists' and technicians'

- perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. *Journal of the American Pharmacists Association* 45 (1): 23-32, 2005.
75. Johnson, B.A., Swift, R.M., Addolorato, G., Ciraulo, D.A., Myrick, H.: Safety and efficacy of GABAergic medications for treating alcoholism. *Alcoholism: Clinical and Experimental Research* 29 (2): 248-254, 2005.
  76. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wallace, C., Wells, L.T., Wang, Y.: Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. *Psychopharmacology* 178 (2-3): 296-302, 2005.
  77. Wurst, F.M., Alling, C., Aradottir, S., Pragst, F., Allen, J.P., Weinmann, W., Marmillot, P., Ghosh, P., Lakshman, R., Skipper, G.E., Neumann, T., Spies, C., Javors, M., Johnson, B.A., Ait-Daoud, N., Akhtar, F., Roache, J.D., Litten, R.: Emerging biomarkers: new directions and clinical applications. *Alcoholism: Clinical and Experimental Research* 29 (3): 465-473, 2005.
  78. Garbutt, J.C., Kranzler, H.R., O'Malley, S.S., Gastfriend, D.R., Pettinati, H.M., Silverman, B.L., Loewy, J.W., Ehrich, E.W., Vivitrex Study Group: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA: The Journal of the American Medical Association* 293 (13): 1617-1625, 2005.
  79. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wallace, C., Wells, L., Dawes, M., Wang, Y.: Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. *The International Journal of Neuropsychopharmacology* 8 (2): 203-213, 2005.
  80. Johnson, B.A., Wells, L.T., Roache, J.D., Wallace, C., Ait-Daoud, N., Wang, Y.: Isradipine decreases the hemodynamic response of cocaine and methamphetamine: results from two human laboratory studies. *American Journal of Hypertension* 18 (6): 813-822, 2005.
  81. Dawes, M.A., Johnson, B.A., Ait-Daoud, N., Ma, J.Z., Cornelius, J.R.: A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. *Addictive Behaviors* 30 (6): 1077-1085, 2005.
  82. Johnson, B.A., Dawes, M.A., Roache, J.D., Wells, L.T., Ait-Daoud, N., Mauldin, J.B., Wang, Y., Lancaster, J.L., Fox, P.T.: Acute intravenous low- and high-dose cocaine reduces quantitative global and regional cerebral blood flow in recently abstinent subjects with cocaine use disorder. *Journal of Cerebral Blood Flow and Metabolism* 25 (7): 928-936, 2005.
  83. Johnson, B.A., Ait-Daoud, N., Akhtar, F.Z., Javors, M.A.: Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. *Archives of Internal Medicine* 165 (14): 1600-1605, 2005.
  84. Wurst, F.M., Tabakoff, B., Alling, C., Aradottir, S., Wiesbeck, G.A., Müller-Spahn, F., Pragst, F., Johnson, B., Javors, M., Ait-Daoud, N., Skipper, G.E., Spies, C., Nachbar, Y., Lesch, O., Ramskogler, K., Hartmann, S., Wolfersdorf, M., Dresen, S., Weinmann, W., Hines, L., Kaiser, A., Lu, R.-B., Ko, H.-C., Huang, S.-Y., Wang, T.-J., Wu, Y.-S., Whitfield, J., Snell, L.D., Wu, C., Hoffman, P.L.: World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. *Alcoholism: Clinical and Experimental Research* 29 (7): 1268-1275, 2005.
  85. Johnson, B.A., Ait-Daoud, N., Roache, J.D.: The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. *Journal of Studies on Alcohol* (suppl 15): 157-167, 2005.
  86. Johnson, B.A., Mann, K., Willenbring, M.L., Litten, R.Z., Swift, R.M., Lesch, O.M., Berglund, M.: Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. *Alcoholism: Clinical and Experimental Research* 29 (8): 1528-1540, 2005.

87. Ait-Daoud, N., Wiesbeck, G.A., Bienkowski, P., Li, M.D., Pfützner, R.H., Singer, M.V., Lesch, O.M., Johnson, B.A.: Comorbid alcohol and nicotine dependence: from the biomolecular basis to clinical consequences. *Alcoholism: Clinical and Experimental Research* 29 (8): 1541-1549, 2005.
88. Johnson, B.A.: Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. *CNS Drugs* 19 (10): 873-896, 2005.
89. Dawes, M.A., Johnson, B.A., Ma, J.Z., Ait-Daoud, N., Thomas, S.E., Cornelius, J.R.: Reductions in and relations between 'craving' and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. *Addictive Behaviors* 30 (9): 1630-1637, 2005.
90. Roache, J.D., Johnson, B.A., Ait-Daoud, N., Mauldin, J.B., Thornton, J.E., Wells, L.T., Murff, W.L.: Effects of repeated-dose isradipine on the abuse liability of cocaine. *Experimental and Clinical Psychopharmacology* 13 (4): 319-326, 2005.
91. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wallace, C.L., Wells, L.T., Wang, Y., Dawes, M.A.: Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. *The International Journal of Neuropsychopharmacology* 8 (4): 549-556, 2005.
92. Johnson, B.A., Koob, G.F., Schuckit, M.A., Mason, B.J., Ait-Daoud, N.: Understanding and treating alcohol dependence. *Alcoholism: Clinical and Experimental Research* 30 (3): 567-584, 2006.
93. Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mason, B.J., Mattson, M.E., Miller, W.R., Pettinati, H.M., Randall, C.L., Swift, R., Weiss, R.D., Williams, L.D., Zweben, A., for The COMBINE Study Research Group: Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE Study: a randomized controlled trial. *JAMA: The Journal of the American Medical Association* 295 (17): 2003-2017, 2006.
94. Johnson, B.A.: A synopsis of the pharmacological rationale, properties, and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. *Expert Opinion on Pharmacotherapy* 7 (8): 1065-1073, 2006.
95. Johnson, B.A.: Pills for speedballing or cocaine dependence [invited comment]. *The Lancet* 367 (9524): 1714-1716, 2006.
96. Johnson, B.A.: New weapon to curb smoking: no more excuses to delay treatment [editorial]. *Archives of Internal Medicine* 166 (15): 1547-1550, 2006.
97. Ait-Daoud, N., Malcolm, R.J., Jr., Johnson, B.A.: An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. *Addictive Behaviors* 31 (9): 1628-1649, 2006.
98. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Javors, M.A., Harrison, J.M., Elkashef, A., Mojsiak, J., Li, S.-H., Bloch, D.A.: A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. *Drug and Alcohol Dependence* 84 (3): 256-263, 2006.
99. Ait-Daoud, N., Dameron, Z.C., III, Marzani-Nissen, G.R., Wells, L.T., Johnson, B.A.: Glutaminergic agents for the treatment of alcohol and substance abuse disorders. *Primary Psychiatry* 13 (10): 56-64, 2006.
100. Ma, J.Z., Ait-Daoud, N., Johnson, B.A.: Topiramate reduces the harm of excessive drinking: implications for public health and primary care. *Addiction* 101 (11): 1561-1568, 2006.

101. Ait-Daoud, N., Lynch, W.J., Penberthy, J.K., Breland, A.B., Marzani-Nissen, G.R., Johnson, B.A.: Treating smoking dependence in depressed alcoholics. *Alcohol Research & Health* 29 (3): 213-220, 2006.
102. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wells, L.T., Wallace, C.L., Dawes, M.A., Liu, L., Wang, X.-Q.: Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 31 (1): 123-130, 2007.
103. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wells, L.T., Wallace, C.L., Dawes, M.A., Liu, L., Wang, X.-Q.: Effects of acute topiramate dosing on methamphetamine-induced subjective mood. *The International Journal of Neuropsychopharmacology* 10 (1): 85-98, 2007.
104. Johnson, B.A., Wells, L.T., Roache, J.D., Wallace, C.L., Ait-Daoud, N., Dawes, M.A., Liu, L., Wang, X.-Q., Javors, M.A.: Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 31 (2): 455-461, 2007.
105. Penberthy, J.K., Ait-Daoud, N., Breton, M., Kovatchev, B., DiClemente, C.C., Johnson, B.A.: Evaluating readiness and treatment seeking effects in a pharmacotherapy trial for alcohol dependence. *Alcoholism: Clinical and Experimental Research* 31 (9): 1538-1544, 2007.
106. Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M., for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group: Topiramate for treating alcohol dependence: a randomized controlled trial. *JAMA: The Journal of the American Medical Association* 298 (14): 1641-1651, 2007.
107. Johnson, B.A.: Naltrexone long-acting formulation in the treatment of alcohol dependence. *Therapeutics and Clinical Risk Management* 3 (5): 741-749, 2007.
108. Johnson, B.A.: Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. *Biochemical Pharmacology* 75 (1) (special issue on addiction): 34-56, 2008.
109. Donovan, D.M., Anton, R.F., Miller, W.R., Longabaugh, R., Hosking, J.D., Youngblood, M., for the COMBINE Study Research Group: Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. *Journal of Studies on Alcohol and Drugs* 69 (1): 5-13, 2008.
110. Johnson, B.A., Javors, M.A., Roache, J.D., Seneviratne, C., Bergeson, S.E., Ait-Daoud, N., Dawes, M.A., Ma, J.Z.: Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 32 (1): 209-216, 2008.
111. Johnson, B.A., Ait-Daoud, N., Elkashef, A.M., Smith, E.V., Kahn, R., Vocci, F., Li, S.-H., Bloch, D.A., Methamphetamine Study Group: A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. *The International Journal of Neuropsychopharmacology* 11 (1): 1-14, 2008.
112. Soyka, M., Kranzler, H.R., Berglund, M., Gorelick, D., Hesselbrock, V., Johnson, B.A., Möller, H.-J., The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, Part 1: alcoholism. *The World Journal of Biological Psychiatry* 9 (1): 6-23, 2008.
113. Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., Addolorato, G., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M., for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group: Improvement of physical health and quality of life of alcohol-

- dependent individuals with topiramate treatment: US multisite randomized controlled trial. *Archives of Internal Medicine* 168 (11): 1188-1199, 2008.
114. Liu, L., Ma, J.Z., Johnson, B.A.: A multi-level two-part random effects model, with application to an alcohol-dependence study. *Statistics in Medicine* 27 (18): 3528-3539, 2008.
  115. Roache, J.D., Wang, Y., Ait-Daoud, N., Johnson, B.A.: Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. *Alcoholism: Clinical and Experimental Research* 32 (8): 1502-1512, 2008.
  116. Zarkin, G.A., Bray, J.W., Aldridge, A., Mitra, D., Mills, M.J., Couper, D.J., Cisler, R.A., for the COMBINE Cost-Effectiveness Research Group: Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. *Archives of General Psychiatry* 65 (10): 1214-1221, 2008.
  117. Weiss, R.D., O'Malley, S.S., Hosking, J.D., LoCastro, J.S., Swift, R., for the COMBINE Study Research Group: Do patients with alcohol dependence respond to placebo? Results from the COMBINE study. *Journal of Studies on Alcohol and Drugs* 69 (6): 878-884, 2008.
  118. Seneviratne, C., Huang, W., Ait-Daoud, N., Li, M.D., Johnson, B.A.: Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. *Alcoholism: Clinical and Experimental Research* 33 (2): 332-339, 2009.
  119. Ait-Daoud, N., Roache, J.D., Dawes, M.A., Liu, L., Wang, X.-Q., Javors, M.A., Seneviratne, C., Johnson, B.A.: Can serotonin transporter genotype predict craving in alcoholism? *Alcoholism: Clinical and Experimental Research* 33 (8): 1329-1335, 2009.
  120. Seneviratne, C., Ait-Daoud, N., Ma, J.Z., Chen, G., Johnson, B.A., Li, M.D.: Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. *Neuropsychopharmacology* 34 (11): 2442-2449, 2009.
  121. Dawes, M.A., Roache, J.D., Javors, M.A., Bergeson, S.E., Richard, D.M., Mathias, C.W., Ait-Daoud, N., Dougherty, D.M., Johnson, B.A.: Drinking histories in alcohol-use-disordered youth: preliminary findings on relationships to platelet serotonin transporter expression with genotypes of the serotonin transporter. *Journal of Studies on Alcohol and Drugs* 70 (6): 899-907, 2009.
  122. Breslin, F.J., Johnson, B.A., Lynch, W.J.: Effect of topiramate treatment on ethanol consumption in rats. *Psychopharmacology* 207 (4): 529-534, 2010.
  123. Johnson, B.A.: Medication treatment of different types of alcoholism. *The American Journal of Psychiatry* 167 (6): 630-639, 2010.
  124. Johnson, B.A., Ait-Daoud, N.: Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. *Current Pharmaceutical Design* 16 (19) (special issue: Old and new pharmacotherapies in the management of patients with alcohol dependence; Addolorato, G., Leggio, L., Eds.): 2103-2112, 2010.
  125. Johnson, B.A., Elkashef, A.M., Seneviratne, C., Ait-Daoud, N., Kahn, R., Li, S.-H., Bloch, D.A., Holmes, T.H., Wang, X.-Q., Vocci, F.J., Jr., Li, M.D., Methamphetamine Study Group: Association between genotype of the serotonin transporter-linked polymorphic region of the serotonin transporter gene and age of onset of methamphetamine use: a preliminary analysis. *Frontiers in Psychiatry* 1 (Article 145): 1-8, November 1, 2010.
  126. Falk, D., Wang, X.-Q., Liu, L., Fertig, J., Mattson, M., Ryan, M., Johnson, B., Stout, R., Litten, R.Z.: Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. *Alcoholism: Clinical and Experimental Research* 34 (12): 2022-2034, 2010.
  127. Johnson, B.A., Ait-Daoud, N., Seneviratne, C., Roache, J.D., Javors, M.A., Wang, X.-Q., Liu, L., Penberthy, J.K., DiClemente, C.C., Li, M.D.: Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. *The American Journal of Psychiatry* 168 (3): 265-275, 2011. Correction in 168 (7): 756, 2011.

128. Johnson, B.A., Messing, R.O., Charness, M.E., Crabbe, J.C., Goldman, M.S., Harris, R.A., Kranzler, H.R., Mitchell, M.C., Jr., Nixon, S.J., Riley, E.P., Schuckit, M.A., Sher, K.J., Thomas, J.D.: Should the reorganization of addiction-related research across all the National Institutes of Health be structural?—The devil is truly in the details. *Alcoholism: Clinical and Experimental Research* 35 (4): 572-580, 2011.
129. Johnson, B.A., Messing, R.O., Charness, M.E., Crabbe, J.C., Goldman, M.S., Harris, R.A., Kranzler, H.R., Mitchell, M.C., Jr., Nixon, S.J., Riley, E.P., Schuckit, M.A., Sher, K.J., Thomas, J.D.: How should addiction-related research at the National Institutes of Health be reorganized? *Frontiers in Psychiatry* 2 (Article 2): 1-3, May 3, 2011.
130. Penberthy, J.K., Hook, J.N., Vaughan, M.D., Davis, D.E., Wagley, J.N., DiClemente, C.C., Johnson, B.A.: Impact of motivational changes on drinking outcomes in pharmacobehavioral treatment for alcohol dependence. *Alcoholism: Clinical and Experimental Research* 35 (9): 1694-1704, 2011.
131. Lynch, W.J., Bond, C., Breslin, F.J., Johnson, B.A.: Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. *Psychopharmacology* 217 (1): 3-12, 2011.
132. Kovatchev, B., Breton, M., Johnson, B.: *In silico* models of alcohol dependence and treatment. *Frontiers in Psychiatry* 3 (Article 4): 1-14, February 3, 2012.
133. Ait-Daoud, N., Seneviratne, C., Smith, J.B., Roache, J.D., Dawes, M.A., Liu, L., Wang, X.-Q., Johnson, B.A.: Preliminary evidence for cue-induced alcohol craving modulated by serotonin transporter gene polymorphism rs1042173. *Frontiers in Psychiatry* 3 (Article 6): 1-5, February 16, 2012.
134. Litten, R.Z., Fertig, J.B., Falk, D.E., Ryan, M.L., Mattson, M.E., Collins, J.F., Murtaugh, C., Ciraulo, D., Green, A.I., Johnson, B., Pettinati, H., Swift, R., Afshar, M., Brunette, M.F., Ait-Daoud Tiouririne, N., Kampman, K., Stout, R., the NCIG-001 Study Group: A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research* 36 (3): 406-416, 2012.
135. Vaughan, M.D., Hook, J.N., Wagley, J.N., Davis, D.E., Hill, C., Johnson, B.A., Penberthy, J.K.: Changes in affect and drinking outcomes in a pharmacobehavioral trial for alcohol dependence. *Addictive Disorders & Their Treatment* 11 (1): 14-25, 2012.
136. Seneviratne, C., Johnson, B.A.: Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. *Frontiers in Psychiatry* 3 (Article 23): 1-7, March 28, 2012.
137. Elkashef, A., Kahn, R., Yu, E., Iturriaga, E., Li, S.-H., Anderson, A., Chiang, N., Ait-Daoud, N., Weiss, D., McSherry, F., Serpi, T., Rawson, R., Hrymoc, M., Weis, D., McCann, M., Pham, T., Stock, C., Dickinson, R., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., Li, M.D., Johnson, B.A.: Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. *Addiction* 107 (7): 1297-1306, 2012. Correction in 107 (9): 1718, 2012.
138. Fertig, J.B., Ryan, M.L., Falk, D.E., Litten, R.Z., Mattson, M.E., Ransom, J., Rickman, W.J., Scott, C., Ciraulo, D., Green, A.I., Tiouririne, N.A., Johnson, B., Pettinati, H., Strain, E.C., Devine, E., Brunette, M.F., Kampman, K., Tompkins, D.A., Stout, R., the NCIG 002 Study Group: A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research* 36 (8): 1421-1430, 2012.

139. Chen, J., Johnson, B.A., Wang, X.-Q., O'Quigley, J., Isaac, M., Zhang, D., Liu, L.: Trajectory analyses in alcohol treatment research. *Alcoholism: Clinical and Experimental Research* 36 (8): 1442-1448, 2012.
140. Wages, N.A., Liu, L., O'Quigley, J., Johnson, B.A.: Obtaining the optimal dose in alcohol dependence studies. *Frontiers in Psychiatry* 3 (Article 100): 1-5, November 22, 2012.
141. Chen, J., Liu, L., Johnson, B.A., O'Quigley, J.: Penalized likelihood estimation for semiparametric mixed models, with application to alcohol treatment research. *Statistics in Medicine* 32 (2): 335-346, 2013.
142. Johnson, B.A., Roache, J.D., Ait-Daoud, N., Gunderson, E.W., Haughey, H.M., Wang, X.-Q., Liu, L.: Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. *Addiction Biology* 18 (3): 405-416, 2013.
143. Ma, J.Z., Johnson, B.A., Yu, E., Weiss, D., McSherry, F., Saadvandi, J., Iturriaga, E., Ait-Daoud, N., Rawson, R.A., Hrymoc, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., Weis, D., McCann, M., Pham, T., Stock, C., Dickinson, R., Elkashef, A., Li, M.D.: Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. *Drug and Alcohol Dependence* 130 (1-3): 45-51, 2013.
144. Litten, R.Z., Ryan, M.L., Fertig, J.B., Falk, D.E., Johnson, B.A., Dunn, K.E., Green, A.I., Pettinati, H.M., Ciraulo, D.A., Sarid-Segal, O., Kampman, K., Brunette, M.F., Strain, E.C., Tiouririne, N.A., Ransom, J., Scott, C., Stout, R., for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group: A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. *Journal of Addiction Medicine* 7 (4): 277-286, 2013.
145. Johnson, B.A., Ait-Daoud, N., Wang, X.-Q., Penberthy, J.K., Javors, M.A., Seneviratne, C., Liu, L.: Topiramate for the treatment of cocaine addiction: A randomized clinical trial. *JAMA Psychiatry* 70 (12):1338-1346, 2013.
146. Liu, L., Strawderman, R.L., Johnson, B.A., O'Quigley, J.M.: Analyzing repeated measures semi-continuous data, with application to an alcohol dependence study. *Statistical Methods in Medical Research*, Stat Med Res, April 2, 2012, <http://smm.sagepub.com/content/early/2012/04/01/0962280212443324>.
147. Seneviratne, C., Franklin, J., Beckett, K., Ma, J.Z., Ait-Daoud, N., Payne, T.J., Johnson, B.A., Li, M.D.: Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT<sub>3</sub> receptor subunits A and B in alcohol dependence. *Human Genetics*, 132:1165-1176, 2013.
148. Johnson, B.A., Seneviratne, C., Wang, X.-Q., Ait-Daoud, N., Li, M.D.: Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT<sub>3</sub> antagonist ondansetron. *The American Journal of Psychiatry*, 70(9):1020-1031, 2013.
149. Johnson, B.A. Pharmacotherapy for alcohol use disorder. UpToDate, 2014. <http://www.uptodate.com/contents/pharmacotherapy-for-alcohol-use-disorder>
150. Johnson, B.A., Seneviratne C.: Alcohol-medical drug interactions. *Handb Clin Neurol*, 125:543-559, 2014. (PMID 25307595)
151. Moore, C.F., Protzuk, O.A., Johnson, B.A., Lynch, W.J.: The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. *Pharmacol Biochem Behav*, 116:107-115, January 2014. (PMID 24252444)
152. Moore, C.F., Lycas, M.D., Bond, C.W., Johnson, B.A., Lynch, W.J.: Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats. *Exp Clin Psychopharmacol*, 22(1):35-42, February 2014. (PMID: 24490709)

153. Falk, D.E., Litten, R.Z., Anton, R.F., Kranzler, H.R., Johnson, B.A., Active Workgroup. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. *J Stud Alcohol Drugs*, 75(2):335-346, March 2014. (PMID 24650828)
154. Li, M.D., Wang, J., Niu, T., Ma, J.Z., Seneviratne, C., Ait-Daoud, N., Saadvandi, J., Morris, R., Weiss, D., Campbell, J., Haning, W., Mawhinney, D.J., Weis, D., McCann, M., Stock, C., Kahn, R., Iturriaga, E., Yu, E., Elkashef, A., Johnson, B.A. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. *BMC Med Genomics*, 12;7:65, December 2014. doi: 10.1186/s12920-014-0065-x. (PMID: 25495887)
155. Hou, J., Seneviratne, C., Su X., Taylor, J., Johnson, B., Wang, X-Q., Zhang, H., Kranzler, H.R., Kang, J., Liu, L. Subgroup Identification in Personalized Treatment of Alcohol Dependence. *Alcoholism: Clinical and Experimental Research* 39(7):1253-1259, 2015.
156. Seneviratne, C., Johnson, B. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. *Alcohol Research: Current Reviews* 37(1): 15-28, 2015.
157. Liu, L., Strawderman, R.L., Johnson BA, O'Quigley JM. Analyzing repeated measures semi-continuous data, with application to an alcohol dependence study. *Stat Methods Med Res* 25(1): 133-152, February 2016.
158. Ryan, M.L., Falk, D.E., Fertig, J.B., Rendenbach-Mueller, B., Katz, D.A., Tracy, K.A., Strain, E.C., Dunn, K.E., Kampman, K., Mahoney, E., Ciraulo, D.A., Sickles Colaneri, L., Ait-Daoud, N., Johnson, B.A., Ransom, J., Scott, C., Koob, G.F., Litten, R.Z., for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence, *Neuropsychopharmacology* accepted article preview 23 September 2016; doi: 10.1038/npp.2016.214.
159. Lui, L., Shih, Y-C.T., Strawderman, R.L., Zhang, D., Johnson, B.A., Chai, H. Statistical analysis of zero-inflated continuous data: a review. *Statistical Science*, 2017 April 18.
160. Johnson, B.A. FDA and EMA Need Homology on Alcohol Outcome Measures – *Semper: Simplicitas est purius modum*. *Alcoholism: Clinical and Experimental Research* 41 (7): 1383-1384, 2017 July.
161. Johnson, B.A. Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder. *Alcoholism: Clinical and Experimental Research* 41 (4): 703-707, 2017 April.
162. Han, H., Liu, L., Su, X., Johnson, B., Sun, L. Variable selection for random effects two-part models. *Statistical Methods in Medical Research*: 2018 July. <https://doi.org/10.1177/0962280218784712>.
163. Falk, DE et al. Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized trials. *JAMA Psychiatry* 2019 Apr 1; 76(4): 374-381.
164. Blevins D, Seneviratne C, Wang XQ, Johnson BA, Ait-Daoud N. A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. *Drug Alcohol Depend*. 2021 Nov 1;228:109074. doi: 10.1016/j.drugalcdep.2021.109074. Epub 2021 Sep 24. PMID: 34600264; PMCID: PMC8595865.
165. Cornell J, Conchas A, Wang XQ, Fink JC, Chen H, Kane MA, Pilli N, Ait-Daoud N, Gorelick DA, Li MD, Johnson BA, Seneviratne C. Validation of serotonin transporter mRNA as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double-blind, crossover trial. *Alcohol Clin Exp Res*. 2022 Oct;46(10):1888-1899. doi: 10.1111/acer.14931. Epub 2022 Sep 11. PMID: 36031718; PMCID: PMC9588643.



166. Addolorato G, Alho H, Bresciani M De Andrade P, Lesch OM, Liu L, Johnson B. Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment. *Eur J Intern Med*. 2024 Sep;127:43-49. doi: 10.1016/j.ejim.2024.03.017. Epub 2024 Mar 23. PMID: 38521730.
167. Johnson B, Alho H, Addolorato G, Lesch OM, Chick J, Liu L, Schuyler V. Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes. *Eur J Intern Med*. 2024 Sep;127:50-62. doi: 10.1016/j.ejim.2024.06.001. Epub 2024 Jun 14. PMID: 38876929.

**Books**

1. Johnson, B.A.: Solving Conundrums in Clinical Psychiatry: A Guide to Viva Voce Examinations, Kluwer Academic Publishers, London, United Kingdom, 1991.
2. Johnson, B.A., Roache, J.D. (Eds.): Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior, Lippincott-Raven Publishers, New York, 1997.
3. Johnson, B.A., Ruiz, P., Galanter, M. (Eds.): Handbook of Clinical Alcoholism Treatment, Lippincott Williams & Wilkins, Baltimore, 2003.
4. Johnson, B.A. (Ed.): Addiction Medicine: Science and Practice, Springer Science+Practice Media, New York, 2011.
5. Johnson, B.A.: The Rehab Myth: New Medications That Conquer Alcoholism, Da Capo Press / Lifelong Books, Cambridge, Massachusetts (in press).
6. Johnson, B.A. (Ed.): Addiction Medicine: Science and Practice, Second Edition. Elsevier, Science+Practice published December 2019
7. Johnson B.A. Six Rings, Clinical Cases in the Science and Practice of Addiction, Awaiting publication

**Book Chapters**

1. Johnson, B.A.: Cannabis. In Glass, I.B. (Ed.): The International Handbook of Addiction Behaviour. Routledge, London, United Kingdom, 1991, pp. 69-76.
2. Hemby, S.E., Johnson, B.A., Dworkin, S.I.: Neurobiological basis of drug reinforcement. In Johnson, B.A., Roache, J.D. (Eds.): Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior, Lippincott-Raven Publishers, New York, 1997, pp. 137-169.
3. Johnson, B.A.: Epidemiology of alcoholism. In Johnson, B.A., Ruiz, P., Galanter, M. (Eds.): Handbook of Clinical Alcoholism Treatment, Lippincott Williams & Wilkins, Baltimore, 2003, pp. 2-9.
4. Ait-Daoud, N., Johnson, B.A.: Medications for the treatment of alcoholism. In Johnson, B.A., Ruiz, P., Galanter, M. (Eds.): Handbook of Clinical Alcoholism Treatment, Lippincott Williams & Wilkins, Baltimore, 2003, pp. 119-130.
5. Johnson, B.A., DiClemente, C.C., Ait-Daoud, N., Stoks, S.M.: Brief Behavioral Compliance Enhancement Treatment (BBCET) Manual. In Johnson, B.A., Ruiz, P., Galanter, M. (Eds.): Handbook of Clinical Alcoholism Treatment, Lippincott Williams & Wilkins, Baltimore, 2003, pp. 282-301.
6. Johnson, B.A., Ait-Daoud, N.: Alcohol: clinical aspects. In Lowinson, J.H., Ruiz, P., Millman, R.B., Langrod, J.G. (Eds.): Substance Abuse: A Comprehensive Textbook, fourth edition, Lippincott Williams & Wilkins, Philadelphia, 2005, pp. 151-163.
7. Johnson, B.A.: Serotonergic compounds: clinical data. In Spanagel, R., Mann, K. (Eds.): Drugs for Relapse Prevention of Alcoholism, Birkhäuser Verlag, Basel, Switzerland, 2005, pp. 107-116.
8. Johnson, B.A.: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine: implications for the treatment of nicotine and alcohol dependence. In Miller, P.M., Kavanagh, D.J. (Eds.): Translation of Addictions Science into Practice: Update and Future Directions, Elsevier Ltd., Amsterdam, The Netherlands, 2007, pp. 167-183.
9. Johnson, B.A.: Disulfiram. In Stolerman, I.P. (Ed.): Encyclopedia of Psychopharmacology, Springer Science+Business Media, New York, 2010, pp. 413-416.
10. Johnson, B.A., Marzani-Nissen, G.: Alcohol: clinical aspects. In Johnson, B.A. (Ed.): Addiction Medicine: Science and Practice, Springer Science+Business Media, New York, 2010, pp. 381-395.

11. Johnson, B.A., Ait-Daoud, N.: Pharmacotherapy for alcoholism and some related psychiatric and addictive disorders: scientific basis and clinical findings. In Johnson, B.A. (Ed.): *Addiction Medicine: Science and Practice*, Springer Science+Business Media, New York, 2010, pp. 943-980.
12. Johnson, B.A.: Opportunities, challenges, and successes in the development of medicines for the treatment of addiction. In Johnson, B.A. (Ed.): *Addiction Medicine: Science and Practice*, Springer Science+Business Media, New York, 2010, pp. 1525-1537.
13. Johnson, B.A.: Pharmacological approaches to the treatment of alcohol dependence in the young. In Saunders, J.B., Rey, J.M. (Eds.): *Young People and Alcohol: Impact, Policy, Prevention, Treatment*, Wiley-Blackwell, West Sussex, United Kingdom, 2011, pp. 271-307.
14. Johnson, B.A., Ait-Daoud, N: Alcohol – Clinical Aspects. *Addiction Medicine*, 1<sup>st</sup> Edition, Elsevier (Ed: Johnson, BA), 2011
15. Johnson, B.A., Seneviratne, C.: Alcohol–medical drug interactions. In Sullivan, E.V., Pfefferbaum, A., (Eds.), Aminoff, M.J., Boller, F., Swaab, D.F. (Series Eds.): *Alcohol and the Nervous System (Handbook of Clinical Neurology, 3<sup>rd</sup> Series)*, Elsevier, Philadelphia , 2014, 125:543-559.
16. Johnson, B.A., Ait-Daoud, N: Alcohol – Clinical Aspects. *Addiction Medicine*, 2<sup>nd</sup> Edition, Elsevier (Ed: Johnson, BA), 2019

### **Theses**

1. Johnson, B.A.: On the phenomenology, classification and associations of obsessive-compulsive symptoms in childhood and adolescence. Master of Philosophy thesis, University of London, 1991.
2. Johnson, B.A.: Impact of 5-HT<sub>3</sub> receptor blockade on the subjective and behavioral effects of drugs of abuse, Doctoral thesis conducted at Oxford University. Thesis archived at University of Glasgow, 1993.
3. Johnson, B.A.: Medications that act at ion channels as treatment for addictive disorders. Doctor of Science thesis conducted in Britain and Texas. Thesis archived at University of Glasgow, 2004.

### **Published Abstracts**

1. Johnson, B.A., Campling, G., Cowen, P.J., Griffiths, P.: The rewarding properties of alcohol are attenuated by 5-HT<sub>3</sub> receptor blockade. Abstracts of the Vth Congress of the European College of Neuropsychopharmacology, Marbella, Spain, 1992. *European Neuropsychopharmacology* 2 (3): 284, 1992.
2. Johnson, B.A., Spiga, R., Franklin, D., Dreyer, C.: The effect of ritanserin on alcohol craving and consumption in alcohol abusing patients. Research Society on Alcoholism Annual Meeting, Steamboat Springs, Colorado, 1995. *Alcoholism: Clinical and Experimental Research* 19 (suppl 2): 17A, 1995.
3. Johnson, B.A., Chen, R., Pineda, E., Williams, E., Ratkos, L., Gonzales, M., Patel, A., Kawasaki, B., Maugans, W., McCauley, B.: Naltrexone for the treatment of dual alcohol and nicotine dependent subjects. Research Society on Alcoholism Annual Meeting, Washington, D.C., 1996. *Alcoholism: Clinical and Experimental Research* 20 (suppl 2): 89A, 1996.
4. Fang, B., Lamki, L., Barron, B., Williams, T., Johnson, B., Wagner, L.K.: Problems encountered in quantification of brain perfusion index (BPI) derived from brain flow acquisition with TC-HMPAO and TC-ECD. Annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine, Austin, Texas, 1996. *Clinical Nuclear Medicine* 21 (2): 169, 1996.
5. Rafieha, S., Spiga, R., Macenski, M., Meisch, R.A., Grabowski, J., Johnson, B.A.: Effects of work requirement and naltrexone on human ethanol self-administration. College on Problems of

- Drug Dependence Annual Meeting, San Juan, Puerto Rico, 1996. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1996: Proceedings of the 58<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 174. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1997, p. 244.
6. Johnson, B., Barron, B., Lamki, N., Wagner, L., Fang, B., Simms, D., Kenny, P., Overton, D., Wells, L., Chen, R., Abramson, D., Minkowitz, H., Shafer, A., Lamki, L.: Brain perfusion abnormalities after acute IV cocaine challenge in abusers shown by quantitative SPECT and brain perfusion index (BPI). Annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine & Cardiac Nuclear Medicine Symposium, New Orleans, Louisiana, 1997. *Clinical Nuclear Medicine* 22 (3): 199, 1997.
  7. Barron, B., Johnson, B., Lamki, N., Wagner, L., Fang, B., Simms, D., Kenny, P., Overton, D., Wells, L., Chen, R., Abramson, D., Minkowitz, H., Shafer, A., Lamki, L.: The effect of acute IV cocaine challenge in abusers on brain perfusion as shown by quantitative SPECT and brain perfusion index (BPI). Society of Nuclear Medicine 44<sup>th</sup> Annual Meeting, San Antonio, Texas, 1997. *Journal of Nuclear Medicine* 38 (5 suppl): 274P-275P, 1997.
  8. Barron, B.J., Johnson, B., Lamki, L.M., Wagner, L.M., Fang, B., Wells, L.T., Abramson, D.: Effect of isradipine on brain perfusion alterations induced by intravenous cocaine: measured by brain perfusion index (BPI) and quantitative SPECT for regional cerebral perfusion. Radiological Society of North America Scientific Assembly and Annual Meeting, Chicago, Illinois, 1997. *Radiology* 205 (P): 314, 1997.
  9. Johnson, B.A., Lamki, L., Simms, D., Chen, R., Fang, B., Barron, B., Wells, L.T., Abramson, D., Dhoother, S., Meisch, R., Oderinde, V.: Reversal of cocaine-induced changes in brain blood flow by isradipine. College on Problems of Drug Dependence Annual Meeting, Nashville, Tennessee, 1997. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1997: Proceedings of the 59<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 178. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1998, p. 96.
  10. Shafer, A., Bordnick, P.S., Simms, D., Chen, R., Oderinde, V., Johnson, B., Schmitz, J.: Relative sensitivity of a laboratory cue reactivity paradigm. College on Problems of Drug Dependence Annual Meeting, Nashville, Tennessee, 1997. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1997: Proceedings of the 59<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 178. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1998, p. 143.
  11. Overton, D., Kenny, P., Wells, L.T., Dhoother, S., Simms, D., Lamki, L., Barron, B., Wagner, L., Fang, B., Chen, R., Meisch, R., Ratkos, L.M., Johnson, B.A.: Cardiovascular effects of cocaine. College on Problems of Drug Dependence Annual Meeting, Nashville, Tennessee, 1997. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1997: Proceedings of the 59<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 178. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1998, p. 207.
  12. Chen, R., Bordnick, P.S., Simms, D., Johnson, B., Schmitz, J.: Cue reactivity and specificity. College on Problems of Drug Dependence Annual Meeting, Nashville, Tennessee, 1997. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1997: Proceedings of the 59<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 178. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1998, p. 144.
  13. Lamki, L., Johnson, B.A., Simms, D., Fang, B., Barron, B., Wagner, L., Bordnick, P.S., Chen, R., Meisch, R., Vogelsson, L., Maugans, W., Overton, D.: Cocaine-related changes in brain blood flow. College on Problems of Drug Dependence Annual Meeting, Nashville, Tennessee, 1997.

- In: L.S. Harris (Ed.): Problems of Drug Dependence, 1997: Proceedings of the 59<sup>th</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 178. Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1998, p. 151.
14. Johnson, B.A., Chen, Y.R., Roache, J.D., Swann, A.C., Bordnick, P.S.: Age of onset as a discriminator between subtypes of alcoholic. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research 22 (suppl 3): 81A, 1998.
  15. Swann, A.C., Chen, Y.R., Johnson, B.A.: Serotonin and alcoholism: relationships between tryptophan availability and clinical features. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research 22 (suppl 3): 85A, 1998.
  16. Bordnick, P.S., Shenberger, M.A., Hassan, F., Doherty, J., Johnson, B.A.: Age of onset and retention in alcohol treatment. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research 22 (suppl 3): 35A, 1998.
  17. Johnson, B.A., Ratkos, L.M., Bordnick, P.S., Shenberger, M.A., Chen, Y.R., Doherty, J., Hassan, F.: Relationship of childhood problems and early onset alcoholism. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research 22 (suppl 3): 76A, 1998.
  18. Javors, M.A., Garza, C.G., Chen, Y.R., Johnson, B.A.: Analysis of the relationship of CDT and GGT measurements to reported drinking over time using a hierarchical linear model. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research 22 (suppl 3): 34A, 1998.
  19. Durgam, S.K., Tiouririne, N.A., Shenberger, M.A., Jones, A.R., Johnson, B.A.: Utility of telephone screen in selecting eligible subjects for enrollment in outpatient clinical trials. Research Society on Alcoholism Annual Meeting, Santa Barbara, California, 1999. Alcoholism: Clinical and Experimental Research 23 (suppl 5): 43A, 1999.
  20. Tiouririne, N.A., Prihoda, T.J., Johnson, B.A.: Are there gender differences between early and late onset alcoholics? Research Society on Alcoholism Annual Meeting, Santa Barbara, California, 1999. Alcoholism: Clinical and Experimental Research 23 (suppl 5): 44A, 1999.
  21. Johnson, B.A., Roache, J.D., DiClemente, C.C., Prihoda, T.J., Tiouririne, N.A., Javors, M.A., Bordnick, P.S.: Ondansetron and alcohol consumption: Preliminary analysis of a double-blind trial. Research Society on Alcoholism Annual Meeting, Santa Barbara, California, 1999. Alcoholism: Clinical and Experimental Research 23 (suppl 5): 81A, 1999.
  22. Tiouririne, N.A., Prihoda, T.J., Johnson, B.A.: Maternal linkage among female alcoholics. College on Problems of Drug Dependence Annual Meeting, Acapulco, Mexico, 1999. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1999: Proceedings of the 61<sup>st</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 180. Bethesda, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1999, p. 99.
  23. Johnson, B.A., Tiouririne, N.A., Bordnick, P.S.: Isradipine does not alter d-methamphetamine-induced hunger state in humans. College on Problems of Drug Dependence Annual Meeting, Acapulco, Mexico, 1999. In: L.S. Harris (Ed.): Problems of Drug Dependence, 1999: Proceedings of the 61<sup>st</sup> Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 180. Bethesda, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse, 1999, p. 129.
  24. Ait-Daoud, N., Prihoda, T., Johnson, B.A.: Safety and effectiveness of combining ondansetron and naltrexone for alcoholism treatment. Collegium Internationale Neuro-psychopharmacologicum Congress, Brussels, Belgium, 2000. The International Journal of Neuropsychopharmacology 3 (suppl

- 1): S311, 2000.
25. Johnson, B.A., Ait-Daoud, N., Roache, J.D., Zanca, N.: Interaction between craving and age of onset as a function of ondansetron treatment among alcoholic patients. Research Society on Alcoholism Annual Meeting, Montreal, Canada, 2001. *Alcoholism: Clinical and Experimental Research* 25 (suppl 5): 144A, 2001.
  26. Ait-Daoud, N., Johnson, B.A., Roache, J.D., Zanca, N.: Correlation between different parameters of craving and drinking among alcoholics in the ondansetron clinical trial. Research Society on Alcoholism Annual Meeting, Montreal, Canada, 2001. *Alcoholism: Clinical and Experimental Research* 25 (suppl 5): 144A, 2001.
  27. Ait-Daoud, N., Johnson, B.A., Roache, J.D., Javors, M., Zanca, N.: Combining ondansetron and naltrexone significantly reduces alcohol drinking among early onset alcoholics: corroboration by serum CDT. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, 2001. *Drug and Alcohol Dependence* 63 (suppl 1): S4-S5, 2001.
  28. Johnson, B.A., Roache, J.D., Ait-Daoud, N.: Comparative pharmacodynamics and kinetics of slow and standard release forms of isradipine — a potential treatment medication for methamphetamine dependence. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, 2001. *Drug and Alcohol Dependence* 63 (suppl 1): S74, 2001.
  29. Murff, W.L., Roache, J.D., Thornton, J.E., Robinson, M., Johnson, B.A.: Behavioral management of sedative ‘self-medicating’ cocaine-dependent patients on a residential psychopharmacology unit. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, 2001. *Drug and Alcohol Dependence* 63 (suppl 1): S111, 2001.
  30. Ait-Daoud, N., Johnson, B.: Combining ondansetron and naltrexone for treating early onset alcoholism: effects on craving, drinking, and their interaction. 7<sup>th</sup> World Congress of Biological Psychiatry, Berlin, Germany, 2001. *World Journal of Biological Psychiatry* 2 (suppl 1): 134S, 2001.
  31. Johnson, B., Ait-Daoud, N.: Ondansetron for treating early onset alcoholism: a pharmacogenetic approach to the subtype concept. 7<sup>th</sup> World Congress of Biological Psychiatry, Berlin, Germany, 2001. *World Journal of Biological Psychiatry* 2 (suppl 1): 40S, 2001.
  32. Johnson, B.A.: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. Society of Biological Psychiatry 56<sup>th</sup> Annual Scientific Program & Convention, New Orleans, Louisiana, 2001. *Biological Psychiatry* 49 (suppl 8S): 14S, 2001.
  33. Ait-Daoud, N., Wells, L., Roache, J.D., Thornton, J.E., Lawson, K., Johnson, B.A.: Sub-acute dosing with isradipine modestly decreases pressor response in phase II lab trials for medications to treat cocaine dependence. College on Problems of Drug Dependence Annual Meeting, Quebec City, Canada, 2002. *Drug and Alcohol Dependence* 66 (suppl 1): S4, 2002.
  34. Johnson, B.A., Roache, J.D., Wells, L., Ait-Daoud, N., Thornton, J.E., Lawson, K.: Sub-acute dosing with isradipine blocks cocaine euphoria and craving in phase II lab trials for medications to treat cocaine dependence. College on Problems of Drug Dependence Annual Meeting, Quebec City, Canada, 2002. *Drug and Alcohol Dependence* 66 (suppl 1): S86-S87, 2002.
  35. Murff, W.L., Roache, J.D., Johnson, B.A., Ait-Daoud, N., Crooks, A.C., Faubion, M.: Side-effect profiles of isradipine in phase II clinical trials of possible effectiveness for cocaine treatment. College on Problems of Drug Dependence Annual Meeting, Quebec City, Canada, 2002. *Drug and Alcohol Dependence* 66 (suppl 1): S125, 2002.
  36. Roache, J.D., Johnson, B.A., Lamb, R.J., Thornton, J.E., Murff, W., Ait-Daoud, N.: A human laboratory model to study internal and external stimulus cues in cocaine reinforcement and relapse prevention. College on Problems of Drug Dependence Annual Meeting, Quebec City, Canada, 2002. *Drug and Alcohol Dependence* 66 (suppl 1): S147, 2002.
  37. Johnson, B.: Ondansetron for treating biological alcoholics: from an hypothesis to treatment, in the symposium titled “Ondansetron for treating biologically predisposed alcoholics”, chaired by

- B. Johnson and I. Grant. Collegium Internationale Neuro-psychofarmacologicum Congress, Montreal, Canada, 2002. The International Journal of Neuropsychopharmacology 5 (suppl 1): S1, 2002.
38. Ait-Daoud, N., Johnson, B.A., Velazquez, M., Lawson, K., Roache, J.D., Javors, M.: Relationship between self report and objective measures of drinking among biological alcoholics. Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002. Alcoholism: Clinical and Experimental Research 26 (suppl 5): 24A, 2002.
  39. Walss-Bass, C., Javors, M.A., Bergeson, S., Roache, J.D., Ait-Daoud, N., Lawson, K., Chang, X., Johnson, B.A.: Differences in platelet serotonin uptake among alcoholic subtypes with variations in allelic genotypes of the serotonin transporter (SERT). Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002. Alcoholism: Clinical and Experimental Research 26 (suppl 5): 8A, 2002.
  40. Hoerster, C., Ait-Daoud, N., Johnson, B., Stoks, S., Sloan, T.: Novelty seeking male and female alcoholics may differ in their propensity for anti-social and mood related behaviors. Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002. Alcoholism: Clinical and Experimental Research 26 (suppl 5): 80A, 2002.
  41. Stoks, S., Johnson, B.A., Roache, J., Sloan, T., Hoerster, C., DiClemente, C.: Utility of craving and temptation as predictors of drinking in a clinical trial. Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002. Alcoholism: Clinical and Experimental Research 26 (suppl 5): 128A, 2002.
  42. Sloan, T., Roache, J., Johnson, B.A., Stoks, S., Hoerster, C.: Pretreatment anxiety may predict ondansetron treatment response among early onset alcoholics. Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002. Alcoholism: Clinical and Experimental Research 26 (suppl 5): 129A, 2002.
  43. Ait-Daoud, N., Johnson, B.: Ondansetron with and without naltrexone as a treatment for biological alcoholism: concepts and updated findings. 15<sup>th</sup> European College of Neuropsychopharmacology Congress, Barcelona, Spain, 2002. European Neuropsychopharmacology 12 (suppl 3): S396, 2002.
  44. Johnson, B., Ait-Daoud, N., Lawson, K.: Dual biomarkers corroborate efficacy of combining ondansetron and naltrexone for the treatment of biological alcoholism. 15<sup>th</sup> European College of Neuropsychopharmacology Congress, Barcelona, Spain, 2002. European Neuropsychopharmacology 12 (suppl 3): S400, 2002.
  45. Johnson, B., Loewy, J., Cehelsky, J., Ford, K., Osborn, C., Bartus, R.T., Ehrich, E.: A Phase II study of Vivitrex<sup>™</sup> (Medisorb<sup>®</sup> naltrexone) in alcohol-dependent adults. American Society of Addiction Medicine Annual Meeting. Journal of Addictive Diseases 22 (2): 114, 2003.
  46. Johnson, B.: Development of topiramate in the treatment of alcoholism, in the symposium titled "Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on topiramate", chaired by B. Johnson and R. Swift. Research Society on Alcoholism Annual Meeting, Fort Lauderdale, Florida, 2003. Alcoholism: Clinical and Experimental Research 27 (suppl 5): 163A, 2003.
  47. Roache, J.D., Johnson, B.A.: Ondansetron as a treatment for "biological" alcoholism, in the symposium titled "Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement and alcoholism", chaired by W.J. McBride and D.M. Lovinger. Research Society on Alcoholism Annual Meeting, Fort Lauderdale, Florida, 2003. Alcoholism: Clinical and Experimental Research 27 (suppl 5): 167A, 2003.
  48. Johnson, B.A.: Mood stabilizers for the treatment of alcoholism: mechanistic basis and new findings, in the symposium titled "Medical treatment of relapse in alcohol dependence", chaired by O. Lesch and B.A. Johnson. European Society for Biomedical Research on Alcoholism

- meeting, Prague, Czech Republic, 2003. *Alcohol and Alcoholism* 38 (5): 468, 2003.
49. Johnson, B.A.: Topiramate's effect on tobacco smoking in those co-dependent on alcohol and nicotine. American Society of Addiction Medicine Annual Meeting, Washington, D.C., 2004. *Journal of Addictive Diseases* 23 (2): 140, 2004.
  50. Johnson, B.A.: Combination of new medication treatments for alcoholism: topiramate and ondansetron. Society of Biological Psychiatry Annual Meeting, New York, 2004. *Biological Psychiatry* 55 (8; suppl 1): 234S, 2004.
  51. Johnson, B.A.: Development of topiramate for the treatment of alcoholism, in the symposium titled "New pharmacologic treatments of alcoholism", chaired by B. Johnson and O. Lesch. Collegium Internationale Neuro-psychofarmacologicum Congress, Paris, France, 2004. *The International Journal of Neuropsychopharmacology* 7 (suppl 1): S12, 2004.
  52. Johnson, B., Ait-Daoud, N.: New data on the safety and effectiveness of topiramate in the treatment of alcohol dependence, in the symposium titled "Safety and efficacy of GABAergic medications for treating alcoholism", chaired by B.A. Johnson and R. M. Swift. Research Society on Alcoholism Annual Meeting, Vancouver, Canada, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 5): 193A, 2004.
  53. Javors, M., Johnson, B., Ait-Daoud, N., Weinmann, W., Wurst, F.M.: Utility of biomarkers in assessing the efficacy of medications for treating alcoholism, in the symposium titled "Emerging biomarkers: new directions and clinical applications", chaired by F.M. Wurst and R. Litten. Research Society on Alcoholism Annual Meeting, Vancouver, Canada, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 5): 189A, 2004.
  54. Javors, M.A., Bergeson, S., Roache, J.D., Ait-Daoud, N., Lawson, K., Chang, X., Seneviratne, C., Johnson, B.A.: Serotonin uptake in platelets among alcoholic subtypes who differ in serotonin transporter genotype, in the symposium titled "Differential response to pharmacotherapy: is it in your genes?", chaired by K. Hutchison. Research Society on Alcoholism Annual Meeting, Vancouver, Canada, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 5): 177A, 2004.
  55. Seneviratne, C., Javors, M.A., Roache, J.D., Ait-Daoud, N., Bergeson, S., Johnson, B.A.: Differences in platelet serotonin uptake among alcoholic subtypes with variations in allelic genotypes of the serotonin transporter (SERT). Poster presentation, Research Society on Alcoholism Annual Meeting, Vancouver, Canada, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 5): 51A, 2004.
  56. Roache, J.D., Wang, Y., Ait-Daoud, N., Johnson, B.A.: Type A/B alcoholism predicts baseline severity, but early vs. late onset predicts ondansetron response. Poster presentation, Research Society on Alcoholism Annual Meeting, Vancouver, Canada, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 5): 114A, 2004.
  57. Johnson, B.: A perspective from academia, in the symposium titled "Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry", chaired by B. Johnson and K. Mann. International Society for Biomedical Research on Alcoholism 12<sup>th</sup> World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 8): 59A, 2004.
  58. Johnson, B.: Pharmacotherapy for promotion of abstinence from nicotine among alcohol-dependent individuals, in the symposium titled "Co-morbid alcohol and nicotine dependence: from the bio-molecular basis to clinical consequences", chaired by N. Ait-Daoud and G. Wiesbeck. International Society for Biomedical Research on Alcoholism 12<sup>th</sup> World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 8): 69A, 2004.



59. Wurst, F.M., Wiesbeck, G.A., Alling, C., Aradottir, S., Pragst, F., Johnson, B., Javors, M., Ait-Daoud, N., Skipper, G.E., Spies, C., Nachbar, Y., Lesch, O., Ramskogler, K., Hartmann, S., Wolfersdorf, M., Dresen, S., Weinmann, W.: Direct ethanol metabolites such as ethyl glucuronide (EtG), fatty acid ethyl esters (FAEEs), phosphatidyl ethanol (PEth) and ethyl sulphate — a new line of sensitive and specific biomarkers, in the symposium titled “The WHO/ISBRA study on state and trait markers of alcohol use and dependence: back to the future”, chaired by B. Tabakoff and F. Wurst. International Society for Biomedical Research on Alcoholism 12<sup>th</sup> World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany, 2004. *Alcoholism: Clinical and Experimental Research* 28 (suppl 8): 53A, 2004.
60. Wurst, F.M., Wiesbeck, G.A., Alling, C., Aradottir, S., Pragst, F., Johnson, B., Javors, M., Ait-Daoud, N., Skipper, G.E., Spies, C., Nachbar, Y., Lesch, O., Ramskogler, K., Hartmann, S., Wolfersdorf, WHO/ISBRA Collaborative Study on Biological State and Trait Markers of Alcohol Use and Dependence, Lauer, J., Halter, C., Weinmann, W.: Direct ethanol metabolites such as ethyl glucuronide (EtG), ethyl sulfate (EtS), ethyl phosphate (EtP), fatty acid ethyl esters (FAEEs) and phosphatidyl ethanol (PEth) — when to use, how to use. Poster presentation, Research Society on Alcoholism Annual Meeting, Santa Barbara, California, 2005. *Alcoholism: Clinical and Experimental Research* 29 (suppl 5): 113A, 2005.
61. Seneviratne, C., Javors, M.A., Roache, J.D., Dawes, M.A., Ait-Daoud, N., Johnson, B.A.: Influence of current drinking on the expression of platelet serotonin transporters across allelic variants of 5'-HTTLPR in treatment seeking adult alcoholics. Poster presentation, Research Society on Alcoholism Annual Meeting, Santa Barbara, California, 2005. *Alcoholism: Clinical and Experimental Research* 29 (suppl 5): 136A, 2005.
62. Johnson, B.A., Ait-Daoud, N.: Genetic and endophenotypic profiling for predicting the efficacy of new medicines, in the symposium titled “Developing new medications to treat alcohol dependence: a theoretical approach toward the next generation of progress”, chaired by B. Johnson and R. Litten. Research Society on Alcoholism Annual Meeting, Baltimore, Maryland, 2006. *Alcoholism: Clinical and Experimental Research* 30 (6s1): 278A, 2006.
63. Wurst, F.M., Wiesbeck, G.A., Aradottir, S., Pragst, F., Johnson, B.A., Lesch, O., Conigrave, K., Weinmann, W.: Direct ethanol metabolites such as ethyl glucuronide (EtG), ethyl sulfate (EtS), fatty acid ethyl esters (FAEEs) and phosphatidyl ethanol (PEth) — their use in diagnosis and treatment, in the symposium titled “The new biomarkers of ethanol intake — how to identify, how to use, when to use”, chaired by M.R. Lakshman and F. Wurst. International Society for Biomedical Research on Alcoholism, World Congress on Alcohol Research, Sydney, Australia, 2006. *Alcoholism: Clinical and Experimental Research* 30 (s2): 52A, 2006.
64. Johnson, B.A.: Association studies of the 5'-HTTLPR gene polymorphism, alcohol craving, and treatment response to ondansetron, in the symposium titled “Serotonergic modulation of behavioural and neurochemical actions of alcohol: evidence from the bench to the clinic”, chaired by L.C. Daws and A. Holmes. International Society for Biomedical Research on Alcoholism, World Congress on Alcohol Research, Sydney, Australia, 2006. *Alcoholism: Clinical and Experimental Research* 30 (s2): 99A, 2006.
65. Johnson, B.A.: Ondansetron for the treatment of stimulant addiction. In: C. Höschl and J.J. López-Ibor (Eds.): Abstract book, 15th Association of European Psychiatrists Congress, Madrid, Spain, 2007. *European Psychiatry* 22 (suppl 1): S191, 2007.
66. Johnson, B.A., Rosenthal, N., Capece, J., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., for the Topiramate for Alcoholism Study Group: Topiramate for the treatment of alcohol dependence: results of a multi-site trial, in the symposium titled “On the development of topiramate as a treatment for alcohol dependence: the next generation of progress in pharmacotherapy”, chaired by B. Johnson and R. Litten. Research Society on Alcoholism

- Annual Meeting, Chicago, Illinois, 2007. *Alcoholism: Clinical and Experimental Research* 31 (s2): 261A, 2007.
67. Lynch, W.J., Johnson, B.A.: Effects of topiramate on alcohol consumption in the rat, in the symposium titled “On the development of topiramate as a treatment for alcohol dependence: the next generation of progress in pharmacotherapy”, chaired by B. Johnson and R. Litten. Research Society on Alcoholism Annual Meeting, Chicago, Illinois, 2007. *Alcoholism: Clinical and Experimental Research* 31 (s2): 261A, 2007.
  68. O’Malley, S.S., Couper, D., Anton, R., Hosking, J., Johnson, B., Mason, B.: Multiple time to event analyses of drinking in the COMBINE study. Poster presentation, Research Society on Alcoholism Annual Meeting, Chicago, Illinois, 2007. *Alcoholism: Clinical and Experimental Research* 31 (s2): 57A, 2007.
  69. Javors, M.A., Koek, W., Johnson, B.A., Marques, P.R., Anthenelli, R.M., Tian, P.Y.: Test retest reliability of %CDT. Poster presentation, Joint Scientific Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, D.C., 2008. *Alcoholism: Clinical and Experimental Research* 32 (6s1): 66A, 2008.
  70. Johnson, B.A., Ait-Daoud, N.: Ondansetron with olanzapine for the treatment of alcohol dependence: preliminary clinical trial. Poster presentation, Joint Scientific Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, D.C., 2008. *Alcoholism: Clinical and Experimental Research* 32 (6s1): 255A, 2008.
  71. Donovan, D., Doyle, S., Anton, R., Johnson, B., LoCastro, J., Mason, B., Pettinati, H., Zweben, A., COMBINE Study Research Group: Prediction of drinking and clinical outcome status following treatment with naltrexone and acamprosate: results from the COMBINE study, in the symposium titled “Towards an individualized treatment in alcohol dependence: results from the US-COMBINE study and German PREDICT study — in honor of past work of Dr. Jack Mendelson”, chaired by K.F. Mann and R.F. Anton. Joint Scientific Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, D.C., 2008. *Alcoholism: Clinical and Experimental Research* 32 (6s1): 281A, 2008.
  72. Johnson, B.A., Roache, J.D., Ait-Daoud, N.: Pharmaceutical trials according to subgroups — an important development in the future, in the workshop titled “Lesch typology computerized assessment for research and therapy”, chaired by O. Lesch and V. Hesselbrock. Joint Scientific Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, D.C., 2008. *Alcoholism: Clinical and Experimental Research* 32 (6s1): 311A, 2008.
  73. Wurst, F.M., Poromaa, I.S., Wiesbeck, G.A., MacFarland, K.D., Alling, C., Aradottir, S., Pragst, F., Johnson, B.A., Javors, M., Roache, J.D., Ait-Daoud, N., Skipper, G.E., Spies, C., Lesch, O., Ramskogler, K., Hartmann, S., Wolfersdorf, M., WHO/ISBRA Collaborative Study on Biological State: New biomarkers of alcohol consumption: diagnostic and therapeutic aspects, in the symposium titled “New biomarkers and devices to detect ethanol intake — benefits, limitations, how and when to use”, chaired by G.E. Skipper, R.Z. Litten, and F. Wurst. Joint Scientific Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, D.C., 2008. *Alcoholism: Clinical and Experimental Research* 32 (6s1): 311A, 2008.
  74. Ait-Daoud, N., Haughey, H.M., Johnson, B.A.: Topiramate for the treatment of women with a dual diagnosis of alcohol dependence and binge eating disorder. Poster presentation, Research Society on Alcoholism Annual Meeting, San Diego, California, 2009. *Alcoholism: Clinical and Experimental Research* 33 (s1): 116A, 2009.

75. Morgan, R.W., Hawkes, W.C., Johnson, B.A., Lynch, W.J.: The alcohol deprivation effect in non-dependent and dependent alcohol preferring (P) rats. Poster presentation, Research Society on Alcoholism Annual Meeting, San Antonio, Texas, 2010. *Alcoholism: Clinical and Experimental Research* 34 (s2): 82A, 2010.
76. Hawkes, W.C., Morgan, R.W., Johnson, B.A., Lynch, W.J.: Effects of acute and chronic topiramate alone and in combination with ondansetron on the reinforcing effects of ethanol in P rats. Poster presentation, Research Society on Alcoholism Annual Meeting, San Antonio, Texas, 2010. *Alcoholism: Clinical and Experimental Research* 34 (s2): 144A, 2010.
77. Falk, D.E., Wang, X., Liu, L., Fertig, J., Mattson, M., Ryan, M., Johnson, B., Stout, R., Litten, R.Z.: Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials, in the INSERM-NIAAA research program titled “Guidelines for alcohol pharmacotherapy trials: hot topics in study design and methods”, chaired and organized by M.M. Murray. International Society for Biomedical Research on Alcoholism World Congress, Paris, France, 2010. *Alcoholism: Clinical and Experimental Research* 34 (s3): 87A, 2010.
78. Johnson, B.A., Liu, L.: Innovative analytic methods of person-centered data for alcohol treatment research, in the INSERM-NIAAA research program titled “Guidelines for alcohol pharmacotherapy trials: hot topics in study design and methods”, chaired and organized by M.M. Murray. International Society for Biomedical Research on Alcoholism World Congress, Paris, France, 2010. *Alcoholism: Clinical and Experimental Research* 34 (s3): 87A, 2010.
79. Morgan, R.W., Johnson, B.A., Lynch, W.J.: Effects of topiramate on the reinforcing effects of ethanol in Wistar and P rats. Poster presentation, Research Society on Alcoholism Annual Meeting, Atlanta, Georgia, 2011. *Alcoholism: Clinical and Experimental Research* 35 (s1): 183A, 2011.
80. Lynch, W.J., Bond, C., Breslin, F.J., Johnson, B.A.: The efficacy of the combination of ondansetron and topiramate varies with severity of drinking in rats. Poster presentation, Research Society on Alcoholism Annual Meeting, Atlanta, Georgia, 2011. *Alcoholism: Clinical and Experimental Research* 35 (s1): 185A, 2011.
81. Johnson, B.A.: Medical treatment. Plenary lecture, European Society for Biomedical Research on Alcoholism meeting, Vienna, Austria, 2011. *Alcohol and Alcoholism* 46 (Suppl 1): i1, 2011.
82. Johnson, B.: Pharmacogenetic approach at the serotonin transporter gene as a method to reduce severe alcohol consumption, in the symposium titled “Genetic differences at the serotonin transporter gene promise a pharmacogenetic approach to the use of ondansetron with and without other agents to treat alcoholism”, chaired by B.A. Johnson and G. Addolorato. European Society for Biomedical Research on Alcoholism meeting, Vienna, Austria, 2011. *Alcohol and Alcoholism* 46 (Suppl 1): i19-i20, 2011.
83. Lynch, W., Bond, C., Breslin, F.J., Johnson, B.A.: Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse, in the symposium titled “Genetic differences at the serotonin transporter gene promise a pharmacogenetic approach to the use of ondansetron with and without other agents to treat alcoholism”, chaired by B.A. Johnson and G. Addolorato. European Society for Biomedical Research on Alcoholism meeting, Vienna, Austria, 2011. *Alcohol and Alcoholism* 46 (Suppl 1): i20, 2011.
84. Johnson, B.: Pharmacogenetic approach to treatment of alcohol dependence with ondansetron, in the symposium titled “Serotonin system in alcoholism: individual differences and treatment”, chaired and organized by B.A. Johnson. European Society for Biomedical Research on Alcoholism meeting, Warsaw, Poland, 2013. *Alcohol and Alcoholism* 48 (Suppl 1): i3, 2013.
85. Seneviratne, C., Franklin, J., Beckett, K., Ma, J., Ait-Daoud, N., Payne, T., Johnson, B., Li, M.: Interactive effects of HTR3A, HTR3B, and SLC6A4 genetic variations on risk for alcohol

dependence in individuals of European descent, in the symposium titled “Serotonin system in alcoholism: individual differences and treatment”, chaired and organized by B.A. Johnson. European Society for Biomedical Research on Alcoholism meeting, Warsaw, Poland, 2013. Alcohol and Alcoholism 48 (Suppl 1): i4, 2013.

### **Book Reviews**

1. Johnson, B.A.: Transcultural Psychiatry. Cox, J.L., author. Book Review. British Journal of Psychiatry 2: 382, 1987.
2. Johnson, B.A.: Neurobiology of Panic Disorder. Ballenger, J.C., author. Book Review. British Journal of Psychiatry 159: 453, 1991.
3. Ait-Daoud, N., Johnson, B.A.: Drugs, the Brain, and Behavior: The Pharmacology of Abuse and Dependence. Book Review. The International Journal of Neuropsychopharmacology 3 (1): 87, 2000.
4. Johnson, B.A.: Substance Abuse: A Comprehensive Textbook, 3<sup>rd</sup> ed. Lowinson, J.H., Ruiz, P., Millman, R.B., Langrod, J.G., editors. Book Review. Journal of Clinical Psychiatry 61 (7): 530, 2000.
5. Johnson, B.A.: Opiate addiction: medical condition or moral failing? Romancing Opiates: Pharmacological Lies and the Addiction Bureaucracy. Dalrymple, T., author. Book Review. The Lancet 369 (9561): 549-550, 2007.
6. Johnson, B.A.: The Substance Abuse Handbook. Ruiz, P., Strain, E.C., Langrod, J.G., editors. Book Review. Journal of Clinical Psychiatry 69 (11): 1837-1838, 2008.
7. Johnson, B.A.: Progress in Neurotherapeutics and Neuropsychopharmacology. Cummings, J.L., editor. Book Review. Journal of Neuro-Ophthalmology 29 (3): 254-255, 2009.

### **Letters to the Editor/Other Professional Communications**

1. Johnson, B.A.: Etiologic factors and prevalence of fractures of the femur in the elderly. University of Glasgow, 1978.
2. Johnson, B.A.: Review of women in medicine in the 1980's. University of Glasgow, 1980.
3. Johnson, B.A.: Trazadone toxicity. British Journal of Hospital Medicine 33 (5): 298, 1985.
4. Cohen, S.I., Johnson, B.A.: Lithium in resistant depression. British Journal of Psychiatry 292: 181, 1986.
5. Cohen, S.I., Johnson, B.A.: Morbid suspicions. British Journal of Psychiatry 292: 181, 1986.
6. Johnson, B.A.: Section 136 and the police. Psychiatric Bulletin 382: 1987.
7. Johnson, B.A.: Paranoid psychosis and AIDS. British Journal of Psychiatry 152: 426, 1988.
8. Johnson, B.A., Smith, B.L., Taylor, P.: Cannabis and schizophrenia. Lancet 1 (8585): 592-593, 1988.
9. Johnson, B.A.: Bankole A Johnson [interview; “Lifeline” column]. Lancet 363 (9404): 256, 2004.
10. Johnson, B.A.: A pill for addiction. NYTimes.com, February 20, 2006.
11. Johnson, B.A., Ait-Daoud, N., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O'Malley, S.S., Swift, R.M.: In reply. JAMA: The Journal of the American Medical Association 299 (4): 406-407, 2008.
12. Johnson, B.A.: We're addicted to rehab. It doesn't even work. The Washington Post, August 8, 2010, page B03.
13. Johnson, B.: Research on AA based on science, not on anecdotes. Lexington Herald-Leader (Kentucky.com), October 3, 2010.
14. Johnson, B.A.: 12-step alcohol rehabs: Prof. Bankole Johnson responds. RushPRNews.com, October 19, 2010.

15. Johnson, B.: Response to Müller and Banas letter. The American Journal of Psychiatry 168 (1): 98-99, 2011.

### **Monographs and Other Miscellaneous Publications**

1. Johnson, B.A., Ciraulo, D.A. (Executive Editors): Addiction medicine: new developments in alcohol dependence [monograph]. Wayne, NJ: Health Learning Systems, 2003.
2. Keck, P.E., Jr. (Executive Editor), Hollander, E., Johnson, B.A., McElroy, S.L., Strakowski, S.M. (Associate Editors): Managing impulsivity in psychiatry [monograph]. Wayne, NJ: Health Learning Systems, 2004.
3. Strain, E.C. (Consensus Panel Chair), Gordon, A.J., Johnson, B.A., McCaul, M.E., Saxon, A., Swift, R., Zweben, A. (Consensus Panelists): Incorporating alcohol pharmacotherapies into medical practice: a Treatment Improvement Protocol (TIP 49) [HHS Publication No. (SMA) 09-4380]. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 2009.
4. Johnson, B.A.: Pharmacologic treatment of alcohol abuse and dependence. In: UpToDate. Gold, M.S., Hermann, R. (Eds.). UpToDate, Waltham, MA, 2010.

### **Major Invited Speeches/Lectures**

#### **1992**

1. The rewarding effects of alcohol are attenuated by 5-HT<sub>3</sub> blockade. Invited lecture, Second International Symposium on Serotonin-from Cell Biology to Pharmacology and Therapeutics, Houston, Texas.

#### **1993**

2. Ondansetron and alcohol-induced reward: pharmacological and pharmacokinetic implications for future research. Invited lecture, European College of Neuropharmacology, Malaga, Spain.
3. Anxiety and alcoholism. Invited lecture, Association of European Neuropsychiatrists, Paris, France.
4. 5-HT/dopamine interactions in the mechanism of action of drugs of abuse. Invited lecture, Louisiana State University Distinguished Neuroscience Lecture series, New Orleans, Louisiana.

#### **1994**

5. Medications development for alcoholism. Invited lecture, Texas Research Society on Alcoholism, Houston, Texas.
6. Review of the role of the 5-HT<sub>3</sub> antagonist, ondansetron, in reducing the rewarding effects of alcohol and the implications for treatment. Invited lecture, NIAAA Treatment Research Branch, Washington, D.C.

#### **1995**

7. Behavioral and cognitive correlates of brain imaging. Invited lecture, An international conference on Drug Abuse in the Decade of the Brain, University of Texas, Houston.

#### **1996**

8. Du Pont Pharma-sponsored 6-part invited lecture series in South Texas on the efficacy of naltrexone for the treatment of alcoholism.
9. Dopamine/serotonin interactions and its implications for addictive behaviors to post-doctoral graduates and students at the University of London Institute of Psychiatry. Invited lecture, London, United Kingdom.

#### **1997**

10. Medications development for substance abuse disorders. Invited lecture, Neuroscience Lecture series, Parke Davis Pharmaceuticals, Detroit, Michigan.

11. Modeling brain ischemia: an analysis using quantitative SPECT. Grand Rounds, University of Texas – Houston Health Science Center.  
**1998**
12. SPECT imaging in drug dependence. Invited lecture, Quarterly Research psychopharmacology lectures between the University of Texas – Houston Health Science Center and Baylor University, Houston, Texas.  
**1999**
13. Joint presentation with Scheer and Company (Connecticut) to the NIAAA Treatment Research Branch on new serotonergic medications for the treatment of alcoholism. Invited lecture, Washington, D.C.
14. Effects of L-type calcium channel antagonists on the ischemic effects of cocaine. Louisiana State University Distinguished Neuroscience Invited Lecture series, New Orleans, Louisiana.
15. On ondansetron and alcohol drinking – ten years in the making. Grand Rounds, Department of Psychiatry, The University of Texas Health Science Center at San Antonio.  
**2000**
16. Ondansetron reduces the drinking of biologically predisposed alcoholics: implications for mechanistic processes at the 5-HT<sub>3</sub> receptors. Invited lecture, Indiana University School of Medicine, Larue Carter Hospital, Indianapolis, Indiana.
17. Advances in the treatment of alcohol and drug addiction. Grand Rounds, St. David's Medical Center, Austin, Texas.
18. Ondansetron and the treatment of early and late onset alcoholics. Invited lecture, Annual Statewide Alcoholism & Substance Abuse Providers of New York State Conference, Bolton Landing, New York.
19. Medications for the treatment of alcohol dependence. Grand Rounds, University of Pennsylvania, Philadelphia, Pennsylvania.  
**2001**
20. Ondansetron and the treatment of alcoholism. Grand Rounds, Charles Drew University, Los Angeles, California.
21. Medications development for alcoholism. Grand Rounds, Northwestern University, Chicago, Illinois.
22. Ondansetron for treating alcoholism – a pharmacogenetic approach. Grand Rounds, Rush Presbyterian Hospital, Chicago, Illinois.
23. The present and future promise of alcoholism treatment – Good news from San Antonio. The San Antonio Rotary Club, San Antonio, Texas.
24. The Southwest Texas Addiction Research & Technology (START) Center – A research center of excellence within The University of Texas Health Science Center at San Antonio. Invited lecture, The University of Texas Health Science Center at San Antonio Planned Giving – Development Board, San Antonio, Texas.
25. New pharmacogenetic hypotheses and treatments of alcohol dependence. Invited lecture, The Annual Mini-Medical School Symposium, The University of Texas Health Science Center at San Antonio.
26. New treatments for alcohol dependence. Invited lecture, Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference, Tucson, Arizona.
27. A pill for the treatment of alcoholism. Health & Life Sciences Conference and Expo. The Greater San Antonio Chamber of Commerce, San Antonio, Texas.
28. Pharmacogenetics of alcoholism treatment. Invited lecture, Oxford University, MRC Psychopharmacology Unit and Neuroscience Center, Oxford, United Kingdom.

29. A pharmacologic approach to the treatment of alcoholism. Grand Rounds, Medical University of South Carolina, Charleston, South Carolina.
30. Ondansetron and naltrexone for the treatment of alcoholism. Invited lecture, Research Seminar at the Alcohol Center, Medical University of South Carolina, Charleston, South Carolina.

**2002**

31. Alcoholism: new potions and remedies: bench to bedside. Invited lecture, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Lewis-Williams Conference and Logistics Management (LCLM), Bethesda, Maryland.
32. Treatments for alcohol addiction. Invited lecture, San Antonio Council on Alcohol and Drug Abuse, San Antonio, Texas.

**2003**

33. Topiramate for the treatment of alcohol dependence. Invited lecture, Association of Psychiatry and Neurology, Vienna, Austria.
34. The future of drugs for treating addiction. Invited presentation before the Editorial Board of *The Lancet*, London, United Kingdom.

**2004**

35. New pharmacological treatments for alcohol dependence. Keynote Luncheon Address at Howard University National Capital Symposium on Mental Health (Bridging addictions: which treatments are right for your patient), Howard University Hospital, Washington, D.C.

**2005**

36. New treatment for alcohol dependence. Grand Rounds, Western State Hospital, Staunton, Virginia.
37. Medications that act at ion channels as treatment for alcohol dependence. Grand Rounds, Wake Forest University, Winston-Salem, North Carolina.
38. Medications that act at ion channels as treatment for alcohol dependence. Journey of Discovery lecture, University of Virginia Health System, Office of Development, Charlottesville, Virginia.
39. Medications development for the treatment of alcohol dependence. Invited presentation, Psychiatric Society of Virginia Annual Fall Meeting, Norfolk, Virginia.
40. Ion channels: new pathways for the treatment of alcohol dependence. Roger E. Meyer Annual Lecture on Addictions, Department of Psychiatry, University of Connecticut, Farmington, Connecticut.
41. Exploring the addict's brain — a journey into the science behind the cravings. Invited presentation for the University of Virginia Health System Development Office, Charlottesville, Virginia.

**2006**

42. Medications that act at ion channels as treatment for addiction. Invited presentation, University of Virginia School of Medicine Research Retreat, White Sulphur Springs, West Virginia.
43. Medications that act at ion channels as treatment for alcohol dependence. Invited lecture, National Addiction Centre, Institute of Psychiatry, London, United Kingdom.
44. Medications that act at ion channels as treatment for addiction. CME session presentation, University of Virginia School of Medicine Reunion Weekend, Charlottesville, Virginia.
45. Medications that act at ion channels as treatment for addiction. Distinguished Psychiatrist Lecture, American Psychiatric Association Annual Meeting, Toronto, Canada.
46. Medications that act at ion channels as treatment for alcohol dependence. Grand Rounds, University of Virginia, Charlottesville, Virginia.
47. A pill for alcoholism. Invited presentation for the University of Virginia Health Services Foundation Board of Directors, Charlottesville, Virginia.

48. Physician Indigent Care Task Force Initiative. Update for the University of Virginia Health Services Foundation Board of Directors, Charlottesville, Virginia.
- 2007**
49. Effects of topiramate on smoking cessation. Invited presentation for the Translational Medication Development for Nicotine Dependence Workshop, National Institute on Drug Abuse, Washington, D.C.
50. Addiction treatment and outpatient detoxification. Joint Primary Care Conference Series lecture, delivered to Internal Medicine and Family Medicine residents, University of Virginia, Charlottesville, Virginia.
51. Topiramate for the treatment of alcohol dependence: single-site and multi-site studies. Invited lecture, University of Virginia Retired Faculty Association luncheon, Charlottesville, Virginia.
52. Principles of drug addiction: an exploration by example. Invited lecture for the graduate course, Behavioral and Cognitive Neuroscience, University of Virginia, Charlottesville, Virginia.
53. Topiramate for the treatment of alcohol dependence. Keynote Lecture, Department of Psychiatry Research Day, Dalhousie University, Halifax, Nova Scotia, Canada.
54. Addictions: how can a habit become an addiction? More Than the Score lecture, Alumni Hall, University of Virginia, Charlottesville, Virginia.
55. Addictions: how can a habit become an addiction? Neurobiology Section Lab Series seminar, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia.
- 2008**
56. Glutamatergic modulation for the treatment of alcohol dependence. National Institute on Alcohol Abuse and Alcoholism seminar, Bethesda, Maryland.
57. Frontiers of addiction research. Virginia 2020 Retreat, Manchester Village, Vermont.
58. Alcoholics, alcoholism, and the law. Invited lecture, University of Virginia School of Law (Psychiatry and Criminal Law class), Charlottesville, Virginia.
59. Pharmacotherapy for alcohol dependence. Slides and audio narration for on-line Master of Science in Addiction Studies course on pharmacotherapies for the treatment of addiction. International Programme in Addiction Studies (IPAS). The University of Adelaide, King's College London, and Virginia Commonwealth University.
- 2009**
60. Overview of the topiramate study population and outcomes. American College of Neuropsychopharmacology "Alcohol Medications Development Workgroup" meeting, Washington, D.C.
61. Principles of drug addiction. Invited lecture for the graduate course, Behavioral and Cognitive Neuroscience, University of Virginia, Charlottesville, Virginia.
62. Pills to treat alcoholism. Solomon Carter Fuller Award Lecture, American Psychiatric Association Annual Meeting, San Francisco, California.
63. New treatments for alcoholism. Invited lecture for a seminar at the Department of Internal Medicine, Catholic University of Rome, Rome, Italy.
64. Pills for the treatment of alcoholism. Invited lecture, Institute of Psychiatry, London, United Kingdom.
65. Pills for alcoholism. Invited lecture, Department of Psychiatry, Oxford University, Oxford, United Kingdom.
66. Alcoholics, alcoholism, and the law. Invited lecture, University of Virginia School of Law (Psychiatry and Criminal Law class), Charlottesville, Virginia.
67. Pharmacogenetic treatment for alcoholism. Grand Rounds, University of Virginia, Charlottesville, Virginia.



## **2010**

68. Pills for the personalized treatment of alcoholism. Grand Rounds, Virginia Commonwealth University, Richmond, Virginia.
69. Personalized medical treatment for alcohol dependence. Invited lecture for the University of Virginia Health System's Payers' Forum, Charlottesville, Virginia.
70. Needs in scientific discovery: capitalizing upon synergies while maintaining research focus. Participation in a panel at a National Institutes of Health Scientific Management Review Board meeting, Bethesda, Maryland.
71. Substance abuse and recovery. Brief presentation and discussion, Richmond Adult Drug Treatment Court, Richmond, Virginia.
72. Alcoholism: from genotype to phenotype. Invited lecture for the British Association for Adoption & Fostering (BAAF) Health Group Advisory Committee meeting, London, United Kingdom.
73. Pharmacogenetic treatment for alcoholism. Invited lecture for the University of Virginia Department of Medicine's 37<sup>th</sup> Annual Edward W. Hook, Jr., MD, Recent Advances in Clinical Medicine Conference, Charlottesville, Virginia.
74. Steps to somewhere. Invited lecture, University of Virginia Curry School of Education (Substance Abuse in Society class), Charlottesville, Virginia.
75. Alcoholics, alcoholism, and the law. Invited lecture, University of Virginia School of Law (Psychiatry and Criminal Law class), Charlottesville, Virginia.

## **2011**

76. Pharmacogenetic approach at the serotonin transporter gene as a method to reduce severe alcohol consumption. Keynote address for the 2<sup>nd</sup> Annual Lloyd C. Elam Symposium at the 50<sup>th</sup> anniversary celebration of the Department of Psychiatry, Meharry Medical College, Nashville, Tennessee.
77. Pills for the personalized treatment of alcoholism. Seminar at the Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, North Carolina.
78. Pharmacogenetic approach at the serotonin transporter gene as a method to reduce severe alcohol consumption. Invited lecture, Centre for Pharmacology and Therapeutics, Imperial College London, London, United Kingdom.
79. State of medicinal treatments for alcohol dependence: challenges and opportunities. Invited lecture, Addictions Department, Institute of Psychiatry, King's College London, London, United Kingdom.
80. Personalized treatment for alcohol dependence. Invited lecture, Neuroscience Group, Department of Psychiatry, Oxford University, Oxford, United Kingdom.
81. Addiction in society. Invited lecture, University of Virginia Curry School of Education (Substance Abuse in Society class), Charlottesville, Virginia.
82. Your pills for your alcoholism. Invited lecture, Medical Scientist Training Program (MSTP) Molecular Medicine Student Seminar Series, University of Virginia, Charlottesville, Virginia.
83. Alcoholics, alcoholism, and the law. Invited lecture, University of Virginia School of Law (Psychiatry and Criminal Law class), Charlottesville, Virginia.

## **2012**

84. Pharmacogenetics of the serotonin system offers new treatment approaches for alcoholism. National Institute on Alcohol Abuse and Alcoholism seminar, Bethesda, Maryland.
85. Musings on decades of progress in alcoholism treatment research. NIAAA Guest Lecture, American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania.
86. Alcoholics, alcoholism, and the law. Invited lecture, University of Virginia School of Law (Psychiatry and Criminal Law class), Charlottesville, Virginia.

### **2013**

87. Personalizing the treatment of alcoholism. Jack Mendelson Honorary Lecture, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland.

### **2014**

88. Personalizing the treatment of alcoholism. Dana African American Lecture, the University of Maryland School of Medicine – Psychiatry Grand Rounds, Baltimore, Maryland.
89. Personalized Medicine Treatment for Alcohol Use Disorders. London Hospitals, Priory Group, United Kingdom.
90. Personalized Medicine Treatment for Alcohol Use Disorders. Imperial College of London, United Kingdom.
91. Personalized Medicine Treatment for Alcohol Use Disorders. University of Maryland Mini-Med School, Baltimore, MD.
92. Personalized Medicine Treatment for Alcohol Use Disorders. Sheppard Pratt Grand Rounds, Baltimore, MD.
93. Personalized Medicine Treatment for Alcohol Use Disorders. The Chancellor’s Award Lecture in Neuroscience at Louisiana State University Health Sciences Center, New Orleans, LA.
94. Personalizing the Medicine Treatment for Alcohol Use Disorders. Sheppard Pratt Health System, Baltimore, MD.

### **2015**

95. Neuroscience & the Psychopharmacology of Addiction Research. University of Maryland School of Medicine Board of Visitors spring meeting, Baltimore, MD. (April 23, 2015)
96. Drexel University Grand Rounds. Personalizing the Treatment for Alcohol Use Disorders. (May 14, 2015)
97. 168<sup>th</sup> APA Annual Meeting in Toronto, Canada. Personalizing the Treatment for Alcohol Use Disorders. (May 19, 2015)
98. Duke University Grand Rounds. Personalizing the Treatment for Alcohol Use Disorders. (May 21, 2015)
99. Lunch Time Research Seminar, University of Maryland School of Social Work. Personalizing the Treatment for Alcohol Use Disorders. (October 8, 2015)
100. The Dark Side of Reward in Addiction and Pain. University of Maryland School of Medicine Festival of Science, Baltimore, MD. (December 11, 2015)

### **2016**

101. Speaking engagement with Fellows on Pharmacologic Treatments. Department of Psychiatry, University of Maryland School of Medicine. (May 11, 2016)
102. Understanding the Brain. Continuing Education & Economic Development Department (CEED) and the Seniors Institute, through the Community College of Baltimore County. (May 3, and May 31, 2016)
103. Clinical Chairs Research Meeting. Department of Psychiatry, University of Maryland School of Medicine. (September 29, 2016)

### **2017**

104. Executive Committee Meeting. Department of Psychiatry, University of Maryland School of Medicine. (October 4, 2017)

### **2019**

105. R. Brinkley Smithers Distinguished Scientist Award Lecture, American Society for Addiction Medicine

## **Presentations at National and International Conferences that did not result in a Published Abstract**

1. Johnson, B.A., Campling, G.M., Griffiths, P., Cowen, P.J.: Rewarding effects of alcohol are attenuated by 5-HT<sub>3</sub> blockade. 2<sup>nd</sup> International Symposium on Serotonin — from Cell Biology to Pharmacology and Therapeutics, Houston, Texas, 1992.
2. Johnson, B.A., Campling, G.M., Rue, J., Griffiths, P., Cowen, P.J.: Ondansetron and alcohol-induced reward: pharmacological and pharmacokinetic implications for future research. European College of Neuropharmacology, Malaga, Spain, 1993.
3. Johnson, B.A., Cowen, P.J.: On 5-HT/dopamine interactions in the mechanism of action of drugs of abuse. Louisiana State University, New Orleans, Louisiana, 1993.
4. Johnson, B.A., Serle, L.: Anxiety and alcoholism. Association of European Psychiatrists, Paris, France, 1993.
5. Johnson, B.A.: The role of serotonin antagonists in alcoholism. Texas Research Society on Alcoholism Annual Meeting, Houston, Texas, 1994.
6. Johnson, B.A., Spiga, R., Schmitz, J., Chen, R.: Effects of the 5-HT<sub>2</sub> antagonist, ritanserin, on cocaine consumption in cocaine dependent subjects. College on Problems of Drug Dependence Annual Meeting, Scottsdale, Arizona, 1995.
7. Johnson, B.A.: Behavioral and cognitive correlates of brain imaging. International Conference on Drug Abuse in the Decade of the Brain, Houston, Texas, 1995.
8. Johnson, B.A. (Chairman): National symposium on atypical neuroleptics for the treatment of schizophrenia. University of Texas – Houston Health Science Center, 1995.
9. Bordnick, P., Wells, L., Lamki, L., Barron, B., Fang, B., Wagner, L., Dhoother, S., Kramer, L., Abramson, D., Huang, D., Ratkos, L., Vogelson, L., Johnson, B.A.: Neuropsychological effects of chronic cocaine use. Regional Meeting of Collegium Internationale Neuro-psychopharmacologicum/Colegio Mexicana de Neuropsicofarmacologia, Acapulco, Mexico, 1997.
10. Wells, L., Bordnick, P., Kenny, P., Overton, D., Dhoother, S., Abramson, D., Wagner, D., Chen, R., Ratkos, L., Vogelson, L., Johnson, B.A.: Intravenous cocaine administration: Effects of isradipine on heart rate. Regional Meeting of Collegium Internationale Neuro-psychopharmacologicum/Colegio Mexicana de Neuropsicofarmacologia, Acapulco, Mexico, 1997.
11. Johnson, B.A., Wagner, L., Lamki, L., Fang, B., Barron, B., Wells, L., Kramer, L., Bordnick, P., Chen, Y., Abramson, D., Dhoother, S., Vogelson, L.: Reliability of a novel quantitative SPECT technique for measuring low, high and normal blood flow states in the brain. American College of Neuropsychopharmacology Annual Meeting, Waikoloa, Hawaii, 1997. 36<sup>th</sup> Annual Meeting Abstracts, 1997, p. 230.
12. Boyle, A.E.L., Stewart, R.B., Macenski, M.J., Spiga, R., Johnson, B.A., Meisch, R.A.: Effects of naltrexone on the self-administration of ethanol in drug-naïve rhesus monkeys. American College of Neuropsychopharmacology Annual Meeting, Waikoloa, Hawaii, 1997. 36<sup>th</sup> Annual Meeting Abstracts, 1997, p. 96.
13. Johnson, B.A., Bordnick, P.S., Shenberger, M.A., Ratkos, L.M., Vogelson, L., Kimble, A.: Alcohol problems and age of onset. American Psychiatric Association Annual Meeting, Toronto, Canada, 1998. New Research Program and Abstracts, 1998, p. 155.
14. Bordnick, P.S., Shenberger, M.A., Ratkos, L.M., Vogelson, L., Huang, D., Kimble, A., Johnson, B.A.: A comparison of neuropsychological deficits in chronic cocaine abusers vs. controls. American Psychiatric Association Annual Meeting, Toronto, Canada, 1998. New Research Program and Abstracts, 1998, p. 71.
15. Johnson, B.A., DiClemente, C.C. and Velasquez, M.M. (Co-Chairpersons): Behavioral and biological correlates of alcohol consumption. Research Society on Alcoholism Annual Scientific

- Meeting, Hilton Head, South Carolina, 1998.
16. Johnson, B.A., Cloninger, C.R., Swann, A.C.: Biological and psychopathological subtypes of alcoholism as correlates of clinical outcome. Research Society on Alcoholism Annual Scientific Meeting, Hilton Head, South Carolina, 1998.
  17. DiClemente, C.C., Carbonari, J.P., Johnson, B.A.: The impact of pharmacological alcoholism treatment on process indicators of change. Research Society on Alcoholism Annual Scientific Meeting, Hilton Head, South Carolina, 1998.
  18. Johnson, B.A., Bordnick, P.S., Tiouririne, N.A.: The impact of the L-type calcium channel blocker, isradipine, on cocaine-induced subjective effects. Poster presentation, XXIst Collegium Internationale Neuro-psychopharmacologicum Congress, Glasgow, Scotland, 1998.
  19. Bordnick, P.S., Wells, L.T., Johnson, B.A., Tiouririne, N.A.: Effects of the L-type calcium channel blocker, isradipine, on methamphetamine-induced cardiovascular response. Poster presentation, XXIst Collegium Internationale Neuro-psychopharmacologicum Congress, Glasgow, Scotland, 1998.
  20. Johnson, B.A., Kaparos, S., Bordnick, P.S., Shenberger, M.A.: Effects of the L-type calcium channel blocker, isradipine, on methamphetamine-induced subjective mood. Poster presentation, XXIst Collegium Internationale Neuro-psychopharmacologicum Congress, Glasgow, Scotland, 1998.
  21. Shenberger, M.A., Tiouririne, N.A., Bordnick, P.S., Johnson, B.A.: Effects of L-type calcium channel blocker, isradipine, on methamphetamine-induced changes in cognitive function. Poster presentation, XXIst Collegium Internationale Neuro-psychopharmacologicum Congress, Glasgow, Scotland, 1998.
  22. Bordnick, P.S., Kimble A., Vogelson, L., Doherty, J., Johnson, B.A.: New methodologies for measuring cocaine craving in the naturalistic environment. Society for Social Work and Research. Austin, Texas, 1999.
  23. Javors, M., France, C., Johnson, B., Prihoda, T.: Measurement of CDT and GGT in rhesus monkeys. 9<sup>th</sup> Annual Texas Research Society on Alcoholism Scientific Meeting, University of Texas Southwestern Allied Health Sciences School, Dallas, Texas, 1999.
  24. Johnson, B.A.: Pharmacotherapies and treatment evaluation systems for alcoholism. Part of the U.S. govt./NIAAA bi-national collaborative meeting with South Africa. U.S. Govt. delegation headed by the Surgeon General. East London, United Kingdom, 1999.
  25. Johnson, B.A., Roache, J.D., Javors, M.A., DiClemente, C.C., Cloninger, C.R., Prihoda, T., Bordnick, P.S., Ait-Daoud, N.: Ondansetron and alcohol consumption: preliminary analysis of double-blind trial. American Society of Addiction Medicine Annual Meeting, New York, New York, 1999.
  26. Johnson, B.A.: Agonists and ecstasy. College on Problems of Drug Dependence Annual Meeting, Acapulco, Mexico, 1999.
  27. Ruiz, P., Guynn, R.W., Krausz, M., Small, D.R., Johnson, B.A., Roache, J.D.: Substance abuse: biopsychosocial considerations. In: Lopez-Ibor, J.J., Sartorius, N., Gaebel, W., Haasen, C. (Eds.): Abstracts of the XI World Congress of Psychiatry: Psychiatry on New Thresholds. Volume I. Hamburg, Germany, 1999, p. 439.
  28. Ait-Daoud, N., Prihoda, T.J., Johnson, B.A.: Placebo response in medication trials for alcoholism. American College of Neuropsychopharmacology Annual Meeting, Acapulco, Mexico, 1999. 38<sup>th</sup> Annual Meeting Abstracts, 1999, p. 116.
  29. Johnson, B.A.: Designing research protocols for pharmacotherapy trials in alcoholism. National Institute on Alcohol Abuse and Alcoholism-sponsored Alcohol Clinical Research Working Group – Issues in Health Disparities Research, Bethesda, Maryland, 2000.
  30. Johnson, B.A.: Pharmacologic treatment research. American Psychiatric Association Annual Meeting, Chicago, Illinois, 2000.

31. Johnson, B.A.: Pharmacological adjuncts in the treatment of alcohol dependence. Research Society on Alcoholism Annual Scientific Meeting, Denver, Colorado, 2000.
32. Johnson, B.A.: A multi-center study of the toxicity and tolerance of naltrexone and acamprosate alone and in combination. Research Society on Alcoholism Annual Scientific Meeting, Denver, Colorado, 2000.
33. Oswald, L.M., Roache, J.D., Johnson, B.A.: Neuroendocrine predictors of benzodiazepine sensitivity and self-administration behavior. Society for Neuroscience Annual Meeting, New Orleans, Louisiana, 2000. Society for Neuroscience Abstracts, Volume 26, Part 2, p. 2271.
34. Johnson, B.A.: Pharmacological adjuncts in the treatment of alcohol dependence. Research Society on Alcoholism Annual Meeting, Montreal, Canada, 2001.
35. Johnson, B.A., Ait-Daoud, N., Javors, M.: Towards a pharmacogenetic understanding of ondansetron's effectiveness at treating biological alcoholism. 8<sup>th</sup> Congress of the European Society for Biomedical Research on Alcoholism, Paris, France, 2001.
36. Ait-Daoud, N., Johnson, B.A.: Combining ondansetron and naltrexone may work synergistically to effectively treat biological alcoholics: a synopsis. 8<sup>th</sup> Congress of the European Society for Biomedical Research on Alcoholism, Paris, France, 2001.
37. Johnson, B.A., Ait-Daoud, N., Roache, J., Zanca, N.: Synopsis and expanded evaluation of ondansetron's effectiveness in treating biological alcoholism. International Congress, World Psychiatric Association, Madrid, Spain, 2001. Abstracts Book, 2001, p. 120.
38. Ait-Daoud, N., Johnson, B.A., Roache, J., Zanca, N., Javors, M.A.: Ondansetron and naltrexone effectively treat biological alcoholism – dual biochemical marker corroboration. International Congress, World Psychiatric Association, Madrid, Spain, 2001. Abstracts Book, 2001, pp. 120-121.
39. Johnson, B.A., Loewy, J.C., Cehelsky, J., Ford, K., Osborn, C., Bartus, R.T., Ehrich, E.: A Phase II study of Medisorb<sup>TM</sup> naltrexone (Vivitrex<sup>TM</sup>) in alcohol-dependent adults. American College of Neuropsychopharmacology Annual Meeting, Waikoloa, Hawaii, 2001. 40<sup>th</sup> Annual Meeting Abstracts, 2001, p. 170.
40. Roache, J.D., Murff, W., Lamb, R.J., Thornton, J.E., Ait-Daoud, N., Johnson, B.A.: A human laboratory study of stimulus cues in cocaine reinforcement and relapse. Texas Research Society on Alcoholism Annual Meeting, Houston, Texas, 2002.
41. Johnson, B.A., Ait-Daoud, N., Roache, J.D., Javors, M.A., Lamb, R.J., Hensler, J.: Pharmacogenomic approaches to alcoholism treatment: toward a hypothesis. Research Society on Alcoholism Annual Meeting, San Francisco, California, 2002.
42. Johnson, B.A.: Ondansetron is effective in treating biological alcoholism. American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania, 2002.
43. Johnson, B.A.: Development of topiramate in the treatment of alcoholism, in the roundtable titled "Addiction medicine: new developments in alcohol dependence", directed by B.A. Johnson. Short Hills, New Jersey, 2003.
44. Johnson, B.A.: Pharmacogenomics: new vistas in treatment for alcoholism, in the roundtable titled "Addiction medicine: new developments in alcohol dependence", directed by B.A. Johnson. Short Hills, New Jersey, 2003.
45. Johnson, B.A.: Topiramate for the treatment of alcohol dependence. New Research Submission, American Psychiatric Association Annual Meeting, San Francisco, California, 2003.
46. Johnson, B., Loewy, J., Cehelsky, J., Ford, K., Osborn, C., Bartus, R.T., Ehrich, E., Silverman, B., for the Vivitrex Phase II Study Group. A phase II study of extended release naltrexone (Vivitrex<sup>®</sup>) in alcohol dependent adults. Poster presentation, Research Society on Alcoholism Annual Meeting, Fort Lauderdale, Florida, 2003.

47. Johnson, B.A.: Effect of topiramate on self-reported and objective measures of alcohol consumption, in the symposium titled “Novel medications and anticonvulsants for the treatment of alcoholism: focus on topiramate”, chaired by B.A. Johnson, O. Lesch, and K. Mann. European Society for Biomedical Research on Alcoholism meeting, Prague, Czech Republic, 2003. Programme and Abstract Book, pp. 8-9.
48. Johnson, B.A.: Pharmacology and clinical experience with topiramate to date, in the symposium titled “Novel medications and anticonvulsants for the treatment of alcoholism: focus on topiramate”, chaired by B.A. Johnson, O. Lesch, and K. Mann. European Society for Biomedical Research on Alcoholism meeting, Prague, Czech Republic, 2003. Programme and Abstract Book, pp. 12-13.
49. Johnson, B.A.: Medications development for the treatment of alcohol dependence, in the symposium titled “Challenges to medications development in alcoholism: an international perspective”, chaired by J. Littleton and P. de Witte. European Society for Biomedical Research on Alcoholism / International Society for Biomedical Research on Alcoholism joint symposium, Prague, Czech Republic, 2003.
50. Johnson, B.A.: Development of topiramate for the treatment of alcoholism, in the satellite symposium titled “Development of a novel anticonvulsant and related compounds for the treatment of alcohol dependence”, chaired by B.A. Johnson, A. Lingford-Hughes, and K.F. Mann. European College of Neuropsychopharmacology meeting, Prague, Czech Republic, 2003. Programme and Abstract Book, pp. 6-7.
51. Johnson, B.A.: Clinical experience with topiramate to date, in the satellite symposium titled “Development of a novel anticonvulsant and related compounds for the treatment of alcohol dependence”, chaired by B.A. Johnson, A. Lingford-Hughes, and K.F. Mann. European College of Neuropsychopharmacology meeting, Prague, Czech Republic, 2003. Programme and Abstract Book, pp. 8-9.
52. Johnson, B.A., Ait-Daoud, N., Bowden, C.L., DiClemente, C.C., Roache, J.D., Lawson, K., Javors, M.A., Ma, J.Z.: Topiramate for the treatment of alcohol dependence. Poster presentation, American Psychiatric Association Institute on Psychiatric Services (APA-IPS), Boston, Massachusetts, 2003.
53. Johnson, B.: Dual diagnosis: alcohol dependence and the bipolar patient, in the industry-supported symposium titled “Beyond bipolar disorder: the importance of treating the total patient”, chaired by P.E. Keck, Jr. U.S. Psychiatric & Mental Health Congress, Orlando, Florida, 2003.
54. Johnson, B.A., Ait-Daoud, N., Bowden, C.L., DiClemente, C.C., Roache, J.D., Lawson, K., Javors, M.A., Ma, J.Z.: Topiramate for the treatment of alcohol dependence. Poster presentation, U.S. Psychiatric & Mental Health Congress, Orlando, Florida, 2003.
55. Johnson, B.A.: The biological basis of alcohol dependence, in the CE/CME satellite symposium titled “New developments in the pharmacologic treatment of alcoholism”, chaired by B.A. Johnson and J. Kub. Southeastern Conference on Alcohol and Drugs, Atlanta, Georgia, 2003.
56. McCaul, M.E., Johnson, B.A.: Pharmacologic treatment of alcohol dependence, in the CE/CME satellite symposium titled “New developments in the pharmacologic treatment of alcoholism”, chaired by B.A. Johnson and J. Kub. Southeastern Conference on Alcohol and Drugs, Atlanta, Georgia, 2003.
57. Johnson, B.: Development of topiramate for the treatment of alcoholism, in the symposium titled “Development of topiramate and anticonvulsants for the treatment of alcohol dependence”, chaired by B. Johnson, A. Zweben, and H. Myrick. American Academy of Addiction Psychiatry meeting, New Orleans, 2003.

58. Johnson, B.: Clinical experience with topiramate to date, in the symposium titled “Development of topiramate and anticonvulsants for the treatment of alcohol dependence”, chaired by B. Johnson, A. Zweben, and H. Myrick. American Academy of Addiction Psychiatry meeting, New Orleans, 2003.
59. Johnson, B.A., Ait-Daoud, N., Ma, J.Z., Akhtar, F.Z., Roache, J.D., Rosenthal, N., Bowden, C.L., DiClemente, C.C., Javors, M.A.: Effects of topiramate on quality of life, psychosocial functioning, and their correlation with heavy drinking in alcohol-dependent individuals. “Hot Topics” poster and oral presentation. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 2003.
60. Ait-Daoud, N., Johnson, B.A., Ma, J.Z., Akhtar, F.Z., Roache, J.D., Rosenthal, N., Bowden, C.L., DiClemente, C.C., Javors, M.A.: Effect of topiramate on nicotine use in individuals co-dependent on nicotine and alcohol. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 2003.
61. Lam, Y.-W.F., Javors, M.A., Ait-Daoud, N., Roache, J.D., Johnson, B.A.: Relative bioavailability of an extemporaneous 4 mg ondansetron capsule versus solution. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 2003.
62. Johnson, B.A.: Topiramate for the treatment of alcohol dependence, in the CME activity titled “Update on treatment approaches for alcohol dependence”. San Antonio, Texas, 2004.
63. Ait-Daoud, N., Johnson, B.A., Akhtar, F.Z., Ma, J.Z.: The effects of topiramate on the psychosocial consequences of drinking among alcohol-dependent individuals. Poster presentation, Society of Biological Psychiatry Annual Meeting, New York, 2004.
64. Johnson, B.A.: How effective are anticonvulsants at improving the overall clinical picture of alcohol dependence?, in the symposium titled “Anticonvulsants for treating multiple components of alcohol-dependence syndrome”, chaired by B.A. Johnson and R.M. Swift. In: Syllabus and Scientific Proceedings in Summary Form: The 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. American Psychiatric Association, Arlington, VA, 2004, p. 183.
65. Johnson, B.A.: Pharmacotherapy for alcoholism, in the industry-supported symposium titled “Bipolar disorder and alcoholism: diagnostic challenges and therapeutic interventions”, chaired by M.A. Frye. In: Syllabus and Scientific Proceedings in Summary Form: The 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. American Psychiatric Association, Arlington, VA, 2004, p. 5.
66. Johnson, B.A., Ait-Daoud, N., Ma, J.Z., Akhtar, F.Z., Roache, J.D., Rosenthal, N., Bowden, C.L., DiClemente, C.C., Javors, M.A.: Topiramate treatment of alcohol dependence: effects on psychosocial functioning and its relationship with heavy drinking. Scientific and Clinical Report Session. In: Syllabus and Scientific Proceedings in Summary Form: The 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. American Psychiatric Association, Arlington, VA, 2004, pp. 94-95.
67. Johnson, B.A., Javors, M.A., DiClemente, C.C., Bowden, C.L., Rosenthal, N., Roache, J.D., Akhtar, F.Z., Ma, J.Z., Ait-Daoud, N.: Topiramate for the treatment of alcohol dependence: effects on psychosocial functioning and its relationship with heavy drinking. New Research Poster, American Psychiatric Association Annual Meeting, New York, 2004.
68. Ait-Daoud, N., Javors, M.A., DiClemente, C.C., Bowden, C.L., Rosenthal, N., Roache, J.D., Akhtar, F.Z., Ma, J.Z., Johnson, B.A.: Topiramate as an agent for smoking cessation? New Research Poster, American Psychiatric Association Annual Meeting, New York, 2004.
69. Johnson, B.A.: Topiramate for the treatment of alcohol dependence, in the NIAAA-sponsored symposium titled “New treatments of addiction: A. Alcohol dependence”, chaired by T.-K. Li

- and D. Sinclair. International Society of Addiction Medicine Annual Meeting, Helsinki, Finland, 2004.
70. Ait-Daoud, N., Johnson, B.A.: Open-label trial of topiramate for treating cocaine dependence, in the oral communications titled “New vistas in treating cocaine dependence”, chaired by B.A. Martell and R.S. Schottenfeld. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico, 2004.
  71. Johnson, B.A., Rawson, R.A., Elkashef, A., Smith, E.V., Campbell, J., Haning, W., Carlton, B., Mawhinney, J., Donovan, R., Weis, D.: Ondansetron for the treatment of methamphetamine dependence. Poster presentation, College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico, 2004.
  72. Smith, E.V., Elkashef, A., Rawson, R.A., Pearce, V.J., Ling, W., Vocci, F., Campbell, J., Haning, W., Mawhinney, J., McCann, M., Weis, D., Johnson, B.A., Newton, T.: 2004 update of NIDA methamphetamine clinical trials. Poster presentation, College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico, 2004.
  73. Johnson, B.: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine: a new vista for the treatment of co-morbid alcohol and nicotine dependence? In: Addictions 2004 — Crossing Boundaries: Implications of Advances in Basic Sciences for the Management of Addiction, Queensland, Australia, 2004.
  74. Johnson, B.A.: New medications: the use of anticonvulsants, both alone and in combination, with various forms of psychotherapy, in the symposium titled “Understanding and treating alcohol dependence”, chaired by B.A. Johnson. American Psychiatric Association Annual Meeting, Atlanta, Georgia, 2005.
  75. Johnson, B.A.: Combination medication strategies for alcoholism, in the symposium titled “New pharmacologic approaches to alcoholism”, chaired by M. Galanter. American Psychiatric Association Annual Meeting, Atlanta, Georgia, 2005.
  76. Johnson, B.A.: Exploring serotonergic transporter variation as a method for understanding differences in treatment response to serotonergic medications among subtypes of alcoholic, in the symposium titled “Antidepressants in the treatment of alcohol dependence — considerations for future research”, chaired by O.M. Lesch. European Society for Biomedical Research on Alcoholism meeting, Canterbury, United Kingdom, 2005.
  77. Johnson, B.A.: Interaction of classification and receptor polymorphism, in the symposium titled “Using subtyping to match alcoholics to pharmacotherapy — a proxy for pharmacogenomics?”, chaired by B.A. Johnson and R.A. Harris. XIIIth World Congress of Psychiatry, World Psychiatric Association, Cairo, Egypt, 2005.
  78. Johnson, B.A.: Topiramate for treating addictions, in the symposium titled “Addiction is a brain disease: implications for treatment”, chaired by F. Vocci. XIIIth World Congress of Psychiatry, World Psychiatric Association, Cairo, Egypt, 2005.
  79. Johnson, B.A.: Dopamine neuromodulation as a treatment approach for developing medications that promote smoking cessation among alcohol-dependent individuals, in the symposium titled “New developments in alcohol and nicotine addiction treatment”, chaired by O.M. Lesch and R.A. Harris. XIIIth World Congress of Psychiatry, World Psychiatric Association, Cairo, Egypt, 2005.
  80. Johnson, B.A.: Acamprosate and other medications for alcohol addiction and relapse prevention, in the session titled “An update on new and pipeline anti-addiction medications”, moderated by F. Vocci. American Society of Addiction Medicine course: The State of the Art in Addiction Medicine 2005: Addiction Across the Lifespan, Washington, D.C., 2005.
  81. Johnson, B.A.: The promise of pharmacogenomics, in the session titled “Pharmacogenomics and other recent developments”, moderated by M. Willenbring and C. O’Brien. American Society of



- Addiction Medicine course: The State of the Art in Addiction Medicine 2005: Addiction Across the Lifespan, Washington, D.C., 2005.
82. Johnson, B.A.: 5-HT<sub>3</sub> antagonism, alcoholism treatment, and possible pharmacogenetic clues, in the session titled “Neural systems and addiction”, chaired by D. Lovinger. Society for Neuroscience Satellite Symposium 2005: The 5-HT<sub>3</sub> Receptor: A Model of Cys-Loop Ligand-Gated Ion Channels, Washington, D.C., 2005.
  83. Johnson, B.A.: Novel concepts in the clinical approach to alcohol dependence, in the symposium titled “Thresholds and limits of addiction”, chaired by B.A. Johnson and P. Ruiz. World Psychiatric Association Juan J. López Ibor Centennial Congress, Madrid, Spain, 2006.
  84. Johnson, B.A.: Development of novel medications for alcoholism, in the NIAAA-sponsored symposium titled “Medications development for alcoholism: from the bench to the patient”. American Society of Addiction Medicine Annual Meeting, San Diego, California, 2006.
  85. Johnson, B.A.: Ondansetron for the treatment of cocaine dependence, in the symposium titled “Treating the clinical consequences 1: drug dependence”, chaired by G. Fischer. European Association of Addiction Therapy 2<sup>nd</sup> Annual Conference, London, United Kingdom, 2006.
  86. Johnson, B.A.: Attacking the “symptom” of drinking: a comprehensive approach to treatment of the alcohol dependence syndrome, in the symposium titled “Overcoming challenges and limitations in the treatment of alcohol dependence”, chaired by B.A. Johnson and P. Ruiz. World Psychiatric Association International Congress, Istanbul, Turkey, 2006.
  87. Ait-Daoud, N., Turker, I., Penberthy, J.K., Johnson, B.A.: Abstinence versus drinking reduction: what is the goal of treatment for alcohol dependence? Poster presentation, World Psychiatric Association International Congress, Istanbul, Turkey, 2006.
  88. Roache, J.D. (presenter), Johnson, B.A.: Dopamine and serotonin systems — their impact on craving and relapse, in the symposium titled “Nicotine and alcohol dependence — is the classification anymore useful for treatment and research?”, chaired by O. Lesch and I. Pelc. International Society for Biomedical Research on Alcoholism 2006 Conference, Sydney, Australia, 2006.
  89. Johnson, B.A., Marzani-Nissen, G. (presenter): Ondansetron for the treatment of cocaine dependence: a preliminary clinical trial. VI World Congress of Depressive Disorders — International Symposium of Addictive Disorders, Mendoza, Argentina, 2006.
  90. Johnson, B.A., Marzani-Nissen, G. (presenter): Treatment of alcohol dependence with anticonvulsants, alone or in combination, and psychotherapy. VI World Congress of Depressive Disorders — International Symposium of Addictive Disorders, Mendoza, Argentina, 2006.
  91. Johnson, B.A.: Recent developments in medications for treating addiction. Keynote Presentation, 37<sup>th</sup> Annual Minnesota Association of Resources for Recovery and Chemical Health Conference, St. Paul, Minnesota, 2006.
  92. Johnson, B.A.: Pharmacological agents demonstrating promise in the treatment of alcohol, nicotine, and cocaine dependence. Breakout Session, 37<sup>th</sup> Annual Minnesota Association of Resources for Recovery and Chemical Health Conference, St. Paul, Minnesota, 2006.
  93. Johnson, B.A.: Neurocognitive and brain imaging effects of stimulant dependence. National Academy of Neuropsychology Conference, San Antonio, Texas, 2006.
  94. Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., for the Topiramate for Alcoholism Study Group: Topiramate for the treatment of alcohol dependence: results of a multi-site trial. Poster presentation, American Psychiatric Association Annual Meeting, San Diego, California, 2007.
  95. Johnson, B.A.: Ondansetron for the treatment of cocaine dependence, in the NIDA Issue Workshop titled “Promising medications for the treatment of cocaine addiction”, chaired by A.

- Elkashef and F. Vocci, Jr. American Psychiatric Association Annual Meeting, San Diego, California, 2007.
96. Johnson, B.A.: Topiramate, in the session titled “New pharmacotherapies for alcohol dependence”, moderated by L.S. Brown, Jr. and R.Z. Litten. American Society of Addiction Medicine course: The State of the Art in Addiction Medicine 2007: The Promise of New Treatments, Washington, D.C., 2007.
  97. Johnson, B.A.: Topiramate for treating alcohol dependence: the multi-site randomized controlled trial, in the symposium titled “Neurobiology and pharmacological treatments for addiction”. I Simposio Internacional de Medicina de la Adiccion: Neurobiologia de la Adiccion al Alcohol y Otras Drogas (First International Symposium on Addiction Medicine: Neurobiology of Addiction to Alcohol and Other Drugs) (co-organized by B.A. Johnson), San José, Costa Rica, 2008.
  98. Ait-Daoud, N., Johnson, B.A.: Brief behavioral compliance enhancement therapy, in the workshop titled “Advances in the use of psychosocial treatments for addictions”. I Simposio Internacional de Medicina de la Adiccion: Neurobiologia de la Adiccion al Alcohol y Otras Drogas (First International Symposium on Addiction Medicine: Neurobiology of Addiction to Alcohol and Other Drugs) (co-organized by B.A. Johnson), San José, Costa Rica, 2008.
  99. Johnson, B.A.: Pharmacotherapies for smoking cessation in patients with addictive disorders, in the NIDA Symposium titled “Smoking cessation in the practice of addiction medicine”, organized by I. Montoya and co-chaired by F. Vocci and J. Khalsa. American Society of Addiction Medicine Annual Meeting, Toronto, Canada, 2008.
  100. Johnson, B.A., Singh, N., Ait-Daoud, N.: Ondansetron with olanzapine for the treatment of alcohol dependence: preliminary clinical trial. Poster presentation, American Psychiatric Association Annual Meeting, Washington, D.C., 2008.
  101. Johnson, B.A.: Overview on the hierarchical levels of alcohol addiction, in the symposium titled “Assessing treatment response in alcoholics through genetic variability, expectancies, computer modeling, and *in silico* experiments”, co-chaired by B.A. Johnson, N. Patapis, and J.K. Penberthy. American Psychological Association 116<sup>th</sup> Annual Convention, Boston, Massachusetts, 2008.
  102. Johnson, B.A.: Drug addiction: a new problem in Costa Rica, its metabolic implications and treatment options. XII Minnesota Costa Rica Medical Week, San José, Costa Rica, 2008.
  103. Johnson, B.A.: Redefining the treatment of alcoholism. American College of Psychiatrists Annual Meeting, Tucson, Arizona, 2009.
  104. Johnson, B.A.: New vistas in treatment for alcohol and drug addiction. II Simposio Internacional de Medicina de la Adiccion: de la Teoria a la Práctica (Second International Symposium on Addiction Medicine), San José, Costa Rica, 2009.
  105. Johnson, B.A.: Pills for the pharmacogenetic treatment of alcohol dependence, in the NIAAA-sponsored symposium titled “Update on genetics and neuroscience”, organized by M. Willenbring. American Society of Addiction Medicine Annual Meeting, New Orleans, Louisiana, 2009.
  106. Johnson, B.A.: An analysis of two promising medications, topiramate and ondansetron, for treating alcohol dependence: results from recent large-scale clinical trials, in the NIAAA-sponsored symposium titled “What’s new in pharmacotherapy for alcohol dependence?”, chaired by R. Litten. American Psychiatric Association Annual Meeting, San Francisco, California, 2009.
  107. Johnson, B.A.: Redefining the treatment of alcoholism. Presentation at a meeting co-sponsored by the U.S. National Institute on Drug Abuse and Mexico’s National Council Against Addictions. Santa Fe, Mexico City, Mexico, 2009.

108. Elkashef, A., Kahn, R., Iturriaga, E., Li, S.-H., Anderson, A., Chiang, N., Li, M., Ait-Daoud, N., Weiss, D., McSherry, F., Serpi, T., Rawson, R., Weis, D., McCann, M., Stock, C., Campbell, J., Haning, W., Mawhinney, J., Yu, E., Johnson, B.: Topiramate for the treatment of methamphetamine addiction. Poster presentation, American College of Neuropsychopharmacology Annual Meeting, Hollywood, Florida, 2009.
109. Johnson, B., Liu, L. (presenter), Ma, J.: A multi-level two-part random effects model, with application to an alcohol dependence study, in the symposium titled “Innovations in statistical modeling of health outcomes – part I”, chaired by M. Khare. The 8<sup>th</sup> International Conference on Health Policy Statistics (American Statistical Association), Washington, D.C., 2010.
110. Johnson, B.A.: Medications for treating alcoholism. Presentation at the Sixth Annual National Institute on Alcohol Abuse and Alcoholism (NIAAA)/Institut National de la Santé et de la Recherche Médicale (INSERM) symposium, Paris, France, 2010.
111. Johnson, B.A.: Pharmacogenetic approach at the serotonin transporter gene as a method to reduce severe alcohol consumption, in the NIAAA panel symposium titled “Personalized medicine: genetic polymorphisms and medications”, chaired by A. Noronha and R. Litten. 51<sup>st</sup> Annual New Research Approaches for Mental Health Interventions (NCDEU) Meeting, sponsored by the American Society of Clinical Psychopharmacology, Boca Raton, Florida, 2011.
112. Johnson, B.A., Lesch, O.: Relapse prevention in alcohol dependence. Workshop, European Society for Biomedical Research on Alcoholism meeting, Vienna, Austria, 2011.
113. Johnson, B.A.: Pharmacogenetic approaches to alcohol dependence: new evidence for ondansetron, in the session titled “Genetics: shaping our understanding of addiction and its treatment”, moderated by R. Litten and F. Vocci. American Society of Addiction Medicine 2011 Course on the State of the Art in Addiction Medicine, Washington, D.C., 2011.
114. Johnson, B.A.: Why and how medicines should be used to treat alcoholism, in the NIAAA symposium titled “Update on medications for alcohol use disorders and their implementation”, organized by R. Huebner and R.Z. Litten. American Society of Addiction Medicine 43<sup>rd</sup> Annual Medical Scientific Conference, Atlanta, Georgia, 2012.
115. Johnson, B.A.: The role of pharmacogenetics in treating alcohol dependence with ondansetron, in the NIAAA-supported symposium titled “Personalized medicine: an update”, chaired by M. Heilig. American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania, 2012.
116. Johnson, B.A.: Pharmacogenetic approach to optimize treatment response to ondansetron in alcohol-dependent patients, in the NIAAA panel symposium titled “Targets to treat alcohol dependence: new human studies”, chaired by R. Litten. 52<sup>nd</sup> Annual New Research Approaches for Mental Health Interventions (NCDEU) Meeting, sponsored by the American Society of Clinical Psychopharmacology, Phoenix, Arizona, 2012.
117. Johnson, B.A.: Brain to behaviour: alcohol and drugs — impact on children and young people. Health Safeguarding Conference, Institute of Child Health, London, United Kingdom, 2012.
118. Johnson, B.A.: Personalized Medicine Treatment for Alcohol Use Disorders. Association for Academic Minority Physicians, AAMP, Alexandria, VA, October, 2014.